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2 Summary of the thesis 
Background: Schizophrenia and bipolar disorder are debilitating disorders. In addition to classic 
psychotic and mood symptoms, frequency of cognitive disturbances and mortality from 
cardiovascular disease are high. Inflammation has been associated with both cognitive 
disturbances and cardiovascular disease. Recent studies have indicated increased inflammation in 
patients with severe mental disorders. However, these studies are small and have a limited 
number of inflammatory markers. This makes it difficult to draw any conclusions about the 
mechanisms involved. No studies have investigated if inflammatory disturbances differ between 
schizophrenia and bipolar disorder. Inflammation has been associated with depression and mania, 
but it is still unclear how it relates to mood symptoms and affective states.  
Aims: The aims were to determine if patients with severe mental disorder have high levels of 
inflammation, if they have a specific inflammatory profile, if inflammatory disturbances differ 
between schizophrenia and bipolar disorder patients, and if inflammatory profile is associated 
with mood symptoms or affective state.  
Methods: 312 patients from a catchment area were included together with 239 healthy controls. 
Patients were diagnosed according to DSM-V, and degree of depression and mania was assessed 
with standard instruments.  
Four general inflammatory markers were measured: Tumor necrosis factor receptor 1 (TNF-R1), 
Interleukin 1 receptor antagonist (IL-1Ra), Interleukin 6 (IL-6) and high-sensitivity CRP (hs-
CRP). Three specific markers were measured: The platelet related inflammatory marker CD40L 
ligand (sCD40L), the endothelial related marker von Willebrand factor (vWf) and the calcium 
related inflammatory marker Osteoprotegerin (OPG). Routine biochemical blood tests and 
clinical characteristics, which could confound associations, were also assessed. 
Results: Patients had a similar immune profile with highly significant increase of TNF-R1, vWf 
and OPG (p<0.000002, p<0.000002, and p=0.01 respectively). The results were significant also 
after control for confounding factors. Contrary to expectations, depressed bipolar disorder 
patients had the lowest levels of inflammation and manic patients had the highest.  
Degree of depressive mood was also inversely correlated with inflammation, which was 
significant for OPG (p=0.0003), IL-1Ra (p=0.001) and IL-6 (p= 0.002).  Patients in manic state 
had significantly higher levels of OPG, vWf, IL-1Ra and sTNF-R1.  
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There were no associations between mood and inflammation in schizophrenia.  
Discussion: The study indicated that the general inflammatory marker TN-R1, as well as 
endothelial and calcium related inflammation may play a role in severe mental illness pathology. 
TNF-R1 has been found to be involved in neuronal plasticity, and related to cognitive 
dysfunction, which is an important clinical characteristic of the disorders. The results are also in 
line with recent findings that endothelial dysfunction and calcium metabolism are involved in the 
pathology. Furthermore, OPG and vWf are risk factors of cardiovascular disease and the high 
levels in patients may be related to their elevated mortality rates.    
It has been fairly well documented that inflammation induces typical sickness behavior, with 
reduced energy, increased sleep and depressive mood. Therefore, it was unexpected that 
inflammation was increased in the manic state. This suggests that there may be other 
inflammatory mechanisms involved. 
Conclusions: Both bipolar disorder and schizophrenia show increased TNF-R1, OPG and vWf. 
This immune profile suggests inflammatory disturbances related to neuroplasticity, endothelial 
function and calcium regulation.  
In bipolar disorder patients, elevated mood is characterized by high levels of inflammation, while 
depressed mood is characterized by low. This suggests that inflammatory disturbances may be 
involved with core psychopathology of bipolar disorder.  
The study supports that inflammatory disturbances are of importance in severe mental disorders.  
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4 General introduction 
4.1 The relationship between psyche and soma 
The relationship between body and soul has been discussed since antiguity. After many years of 
research modern biomedicine established that mental stress increases the risk of somatic illness. 
A putative mechanism is that mental stress suppresses the immune system, which leads to 
impaired defense mechanisms and increased risk of diseases. The association between 
psychological and somatic disease is seen in patients with severe mental disorders, as they are 
highly vulnerable to mental stress and have elevated risk of most diseases. Recent research has 
also suggested that they have immunological disturbances. 
However, it is unknown if they have any specific immune related disturbances making them more 
prone to cardiovascular diseases than for instance metastatic cancer. Recently an intriguing link 
between the immune system and mental function has been found. It was discovered that immune 
molecules are directly involved in an important brain function, memory consolidations. Patients 
with severe mental disorders have reduced memory functioning, and thus one may wonder if both 
their risk of medical disease and of brain function disturbances are immune related.   
Bipolar disorder (BP) and schizophrenia (SCH) have several similarities. Patients with both 
disorders may have psychotic symptoms, mood disturbances, cognitive disturbances and high risk 
of medical diseases. Therefore, it is possible that they also may have the same kind of immune 
disturbances, but this has not yet been investigated.  
A typical immune activation induces symptoms commonly seen in sickness, as increased need for 
sleep, impaired appetite and reduced energy. These symptoms are similar to symptoms seen in 
depression. Manic patients, on the contrary, often have opposite symptoms from those induced by 
typical immune activation. Do depressed patients have opposite kinds of immune disturbances 
than the manic? This is still unknown.  
There are still many unanswered questions regarding the interaction between psychological and 
medical disease. Increased understanding of the pathological mechanisms involved could lead to 
better treatment for both mental and physical diseases.  
To contribute to such increased understanding was the motivation for conducting the present 
work.  
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4.2 Schizophrenia 
4.2.1 Diagnostic definition 
There are no pathognomonic signs for SCH. The disorder is defined by a set of symptoms which 
are described in the Diagnostic and Statistical Manual for Mental Disorders (DSM) [1]. To fulfill 
the diagnostic criteria patients must have had a minimum set of characteristic psychotic 
symptoms (delusions, hallucinations, thought disorders) for at least one month, as well as some 
symptoms of the disorder lasting for at least 6 months. A marked dysfunction must also be 
present.  If affective episodes and psychotic symptoms occur simultaneously, the psychotic 
symptoms must be present at least 2 weeks in the absence of prominent mood symptoms. 
Otherwise, the disorder is classified as schizoaffective disorder. If the duration of symptoms is 
shorter than 6 months, the disorder is classified as schizophreniform disorder. Schizophreniform 
disorder, schizoaffective disorder and schizophrenia are called “schizophrenia spectrum 
disorders”. 
4.2.2 Prevalence and risk factors 
The prevalence of SCH is estimated to be about 0.5 - 1.0 %, being slightly more frequent in the 
male gender [2].  The prevalence is more geographically varied than previously assumed, and is 
higher in urban regions and in the northern latitudes.  Migration and having a father of old age are 
risk factors [2, 3], as well as obstetric complications and prenatal infections  [2]. Drug abuse, 
especially intoxication with cannabis, is associated with elevated frequency of developing 
schizophrenia [2]. There are also some studies indicating that social stress and abuse may 
precipitate psychosis [2]. In addition to these environmental risk factors, SCH has a high 
heritability with heritable estimates of 0.6-0.8 [4].The concordance rate for monozygotic twins is 
approximately 40-50%, indicating that environmental factors are also important  [2].  Recently 
specific genetic risk factors have been identified, as further described in “3.2.3 Genetic 
mechanisms”.   
 
4.2.3 Disease characteristics 
Disease course: Age at onset is usually in adolescence or young adulthood, but patients may also 
get the disorder in childhood or later in adulthood [2]. The course of the disorders differs among 
patients. Some get a chronic disease, never obtaining remission, while others achieve complete 
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remission and do not relapse. A substantial group has a relapsing and remitting disease course 
[5].                                                                                                                  
Many patients report reduced quality of life  and many patients are depressed [2]. Also mania like 
symptoms as grandiosity, agitation and irritability are frequent [6].  According to nationwide 
Swedish register studies, 6% of those who had been admitted to hospital twice, commit suicide. 
The risk of violent crimes is also increased [7]. Those who have poor premorbid function and a 
long duration of untreated psychosis tend to have poorer treatment outcome [2].  Many patients 
do not fully recover and need lifelong treatment and social security services [8]. 
Cognitive impairments: Many patients have slight cognitive deficits, and cognitive 
impairment is one of the most important factors for outcome [9, 10]. The main domains 
affected are executive function, attention and memory.  The patients may have problems with 
complicated reasoning, forgetfulness, learning disabilities and concentration difficulties.  A 
decline in cognitive function mainly occurs in the period of illness onset, although there are 
also some indications that the cognitive impairment progress after illness onset [2, 11].  
Somatic disease: The patients have high mortality, and the lifetime expectancy is reduced by 
approximately 20 years [12]. The disease has high comorbidity with many medical diseases, 
especially of cardiovascular disease [13]. The patients have also been found to have elevated 
frequency of diabetes [14], chronic obstructive lung disease [14] and autoimmune diseases [15].  
The causes of the large excess in mortality rates are uncertain. It has been assumed that poor life 
style habits as little physical activity and high frequency of smoking, as well as side effects of 
medication may be at least partly responsible. Another reason may be that patients with severe 
mental disorders receive poorer somatic health care than the population in general [16, 17].  
4.2.4 Treatment 
Biological treatments: The main medication is antipsychotic agents targeting dopamine 
neurotransmission. They are efficient in 60-80 %of the patients and have a “Number Needed to 
Treat “of 2-5 [18]. They are mainly effective on positive psychotic symptoms, while the effects 
on negative symptoms and cognitive dysfunction are small, if any at all [2]. The first types of 
antipsychotics that were developed in the 1950s have a high selectivity for blocking dopamine 
D2 receptors. They do relatively often induce motor side effects, while the second generation of 
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antipsychotics tends to induce less troublesome side effects of this type due to more balanced 
blocking of dopamine and serotonin receptors [2]. The second-generation antipsychotics have 
however, a tendency to induce serious metabolic side effects. The use of the highly effective 
clozapine, is also limited by its tendency to induce agranulocytosis [2, 19]. 
Psychosocial treatments: Treatment regimens also include psychotherapy, psychoeducative 
family interventions, psychosocial support, and vocational rehabilitation [2]. Due to a negative 
impact of long duration of untreated psychosis, treatment programs for early intervention have 
been developed [2].  
4.2.5 Pathological mechanisms 
Genetic mechanisms: Two years ago, three large whole genome studies from several countries 
found that the five top susceptibility markers for SCH were located in a genetic region called the 
Major Histocompability Complex [20]. As explained in section 3.4.2, this region contains 
important immune related genes. One of the markers that have been replicated also in later 
studies is located near the gene TCF4. The highest expression of this gene is in the brain and in 
the spleen [21]. Its function is not fully known. In the brain it has been found important for 
cognitive function [22],  and in the immune system for the maturing of immune cells [21].   
NOTCH 4 is another of the top susceptibility genes in the MHC region [20]. The role of this gene 
in the brain is also largely unknown, but it is has been found important for endothelial function 
and vascular pathology [23].  
In addition, genes outside the MHC region have been found to confer risk. Genes related to 
calcium and sodium channels as CACNA1c, Neurogranin, and ANK3 are among those most 
replicated [20, 24]. CACNA1c encodes a calcium channel, Neurogranin is involved with long 
term memory formation [20], while ANK3  is involved with regulation of sodium channels in 
neurons [25]. The gene ZNF804a also confers risk of SCH. The risk-associated variant has been 
associated with somewhat better cognitive function in patients, but how it relates to pathology is 
still unclear [26].  
Two other recently discovered risk genes, CSMD1 1 and 2, have been associated with memory 
formation and with the innate immune system/complement (see 3.4.1) [27]. Genetic parts 
encoding Human endogenous retrovirus (HERV-W) have also been implicated in the pathology 
of SCH. HERVs are not encoded by ordinary genes, but are encoded by so-called “junk DNA”, 
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that previously were thought to be without any function. Proteins encoded by HERV-W have 
been found elevated in the serum of SCH [28]. 
Disturbed neurotransmission: Excess dopamine neurotransmission has been regarded as a 
central pathological mechanism in SCH and a range of dopaminergic abnormalities has been 
found. They have been related to limbic structures and affect regulation, as well as to cognition 
motivation and reward  [2]. However, in a substantial part of patients, blocking dopamine with 
antipsychotics does not lead to remission, and current evidence does not support that excess 
dopamine  transmission is the primary cause of the disease [2].  It has been suggested that 
patients may have an underlying glutamatergic abnormality. Excess glutamate may both 
influence dopamine and induce SCH-like symptoms. Glutamate may also be toxic to neurons and 
cause neurodegeneration when in excess, leading to the morphological changes found in patients. 
An important pathological mechanism of glutamate is suggested to be through impact on calcium 
and NMDA receptors [2, 29].   
Neuronal substrates: Reduced brain volumes in specific areas and enlarged ventricles is one of 
the best documented pathological findings in SCH [2]. Large reviews of the imaging studies 
suggest that there are thinner frontal and temporal cortex and reduced subcortical structures, for 
example of the hippocampus [2]. New research indicates that these morphological changes are 
associated with poorer cognitive dysfunction [30, 31]. Most of these changes are present already 
at onset of disease [2], but studies have also reported that  that the morphological changes are 
increasing [2]. According to a recent meta-analysis, the ventricular enlargements progress after 
onset of the disorder [32].  
Immune hypothesis of schizophrenia:  Several authors have proposed that immune related 
disturbances are central causes of SCH. These immune hypotheses are not contradictory to the 
previously mentioned theories about pathology, but provide some novel explanations for how 
immune related gene-environmental interactions may influence pathology [33-36]. Immune 
related genes are among the main genetic risk factors (as described in 3.2.3) and infections are 
among the main environmental risk factors. A large study including 1.2 million children, found 
that infections with two pathogens during pregnancy increased risk of SCH; Cytoplasma virus 
(CMV) and mumps [37]. Two other large studies found the herpes simplex virus 2 (HSV2) 
16 
 
[38]and toxoplasma gondii [39, 40] during pregnancy conferred elevated risk. In addition, high 
levels of cytomegalovirus, coronavirus and measles have been found in first episode patients [41-
44]. According to a meta-analysis SCH patients have higher levels of toxoplasma antibodies [45]. 
Patients do not have higher titers of Herpes simplex 1 (HSV1), but still, this is the only pathogen 
that has been associated with poorer cognitive function in patients. Six studies have found that 
those who have antibodies of HSV1 in their serum have poorer cognitive function [46-51].  This 
suggests that there may be an interaction between herpes virus and pathological mechanisms 
causing cognitive disturbances, which are key characteristics of SCH.  
4.3 Bipolar disorder 
4.3.1 Diagnostic definitions 
The diagnosis of bipolar disorder (BP)  is based on the presence of a certain set of symptoms [1], 
of which none is pathognomonic. To fulfill the diagnostic criteria patients must have had at least 
one major depressive episode and one episode of mania or hypomania. Whether they have had a 
manic episode or only a hypomanic, determines whether the diagnosis is classified as bipolar I 
disorder (BPI) or bipolar II disorder (BPII), respectively. Mania and hypomania have the same 
main symptoms, although mania is a more severe condition than hypomania. A manic episode is 
defined by a distinct period of elevated, expansive or irritable mood. It is accompanied by a set of 
related signs or symptoms as increased self-esteem, energy, and involvement in pleasure-related 
activities.  The need for sleep and rest is reduced. In contrast to hypomania, mania implies 
marked impairment in social functioning and may be characterized by the presence of psychosis 
[1]. 
A major depressive episode is characterized by a distinct period of at least two weeks duration 
with depressed mood or anhedonia, accompanied by symptoms as disturbance of sleep and 
appetite, reduced self-esteem and energy,  agitation/retardation  or suicide thoughts, as well as a 
functional decline [1].  
Between affective episodes, patients may be well functioning without symptoms.  
4.3.2 Prevalence and risk factors 
The prevalence of BP varies across studies, but approximately equals SCH. Prevalence has been 
estimated to 0.6% for BP I, 1.4% for BP II and 2.6% for bipolar spectrum disorders [2, 52]. The 
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prevalence is equally high in men and women [2]. Bipolar disorder has high hereditability, 
estimated to 0, 6-0.8 [2]. Specific genetic risk markers are described in section 3.3.5. Pre- and 
perinatal complications [53], being born during winter or spring  [54], head injuries [55], living in 
an urban district [56]and stressful life events [54] are also associated with increased risk. In 
contrast to SCH, low premorbid IQ is not associated with elevated risk [57]. Whether the risk of 
BP increases after infections in fetal life or in later life is not known.  
4.3.3 Disease characteristics 
Disease course: The onset is usually in adolescence and young adulthood [2]. The duration of 
episodes varies a lot, but most episodes last between two to seven months [58], with depressive 
episodes lasting approximately twice as long as the manic episodes [59].  Many patients 
experience psychotic symptoms [2], and tend to have cognitive impairments resembling those 
seen in SCH [60]. Patients report reduced quality of life, high rates of alcohol and drug abuse [61, 
62], and have highly increased risk of suicide [63].  
Compared to patients with unipolar depression, patients with bipolar depression have a greater 
number of short depressive episodes, are more often psychotic, have larger diurnal mood 
variation and more often hypersomnia [64]. The disorder tends to have an accelerating rate of 
affective episodes and progressive reduction in periods with neutral mood [2]. Fifteen years after 
onset, about one third of patients have persistent unremitting symptoms [2]. 
Somatic disease and mortality: BP patients have an elevated risk of cardiovascular diseases. 
The risk seems to be especially pronounced in mania [65, 66].  A large study also reported that 
they have an increased frequency of 41 out of 44 diseases investigated [67], including 
hypertension, stroke, coagulopathies, headache, neurological diseases, pulmonary disease, AIDS, 
and cancer.  One of the few diseases they have reduced risk of is the immune related cancer 
lymphoma [67]. Their life time expectancy is reduced by than approximately 10 years [68]. 
Cognitive function: According to a prospective study including 50.000 men, poor premorbid IQ 
does not increase risk of BP, in contrast to SCH [57, 69]. After disease onset, patients do have 
cognitive disturbances, which has been found to be present also in euthymic state [70]. Cognitive 
impairments are correlated with poor treatment outcome and psychosocial functioning. Therefore 
experts have suggested that this should be a main treatment target [71, 72].   
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4.3.4  Treatment 
Biological treatments: The main medications for BP are lithium salts and anticonvulsants/mood 
stabilizing agents as valproate [73]. Lithium is regarded the first drug of choice for prevention of 
new episodes as it is more preventive than valproate [73]. Second generation antipsychotics have 
also recently been found to have mood stabilizing properties, preventing relapses of mood 
episodes [74].  Treatment against mania includes antipsychotics and mood stabilizing agents. 
Lithium is fairly effective with a number needed to treat (NNT) of 6 [75, 76].  
These three kinds of medication target different receptors and pathways, but it has recently been 
suggested that impact on glutamate may be an important aspect of lithium, anticonvulsants and 
antipsychotics [77-79].  
Antidepressants are commonly used against bipolar depression, although the evidence for 
effectiveness is sparser than their effect against unipolar depression. They may increase the risk 
of affective shifts. Thus it has been suggested to limit the use of antidepressants in bipolar 
depression [80].  In small studies, bipolar depressed patients have been found to have an equal  
treatment response to Electroconvulsive therapy (ECT) as unipolar depression [81], but there are 
few studies of ECT treatment. 
Psychosocial treatment: Approaches such as psycho-education, cognitive behavior therapy,  and 
family therapy have shown benefits as adjunctive treatments [82]. As in SCH, a long duration of 
untreated illness is associated with poorer outcome [83]. 
4.3.5 Pathological mechanisms 
Genetic mechanisms: It has been difficult to identify the specific genetic factors conferring the 
risk of BP. Many genes susceptibility genes are similar to those found for SCH, but genes in the 
MHC region seem less associated with BP than SCH [24]. In 2008, it was reported that a 
calcium- related gene called CACNA1c conferred risk genes of BP. This has been replicated in 
later studies [84]. This gene has also been associated with cardiovascular disease [85]. Another 
susceptibility gene is important for the function of sodium channels (ANK3), further implicating 
that genes regulating neuronal excitability have impact on the susceptibility [86]. A gene with 
previously unknown function, ZNF804a (C2orf10) is a susceptibility gene for both SCH and BP. 
It has been associated with cognitive function, although studies have found somewhat different 
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results [87]. The only somatic disease that has described association with this gene is a type of 
lymphoma [88]. 
Neuronal processes: According to Post's kindling hypothesis [89], major stress is required to 
trigger the onset of BP. Stress also increases risk of the first relapses. However, the later relapses 
seem to occur more and more independent of stressing life events. Episodes may eventually occur 
autonomously, which could be due to kindling processes in the brain. However, some studies are 
inconsistent with these findings [2].  
Disturbed neurotransmission: No distinct pathology of neuronal function has yet been 
identified in bipolar disorder. However, since lithium and mood stabilizing drugs have effect on 
intracellular signal transduction, much research has been done to clarify these mechanisms. It has 
been found that lithium modifies inositol, and depletion of inositol has been suggested to be a 
central abnormality of BP [90]. Dysregulation of calcium signaling has also been suggested to be 
of importance, and calcium signaling has been reported in several studies [84, 91]. Also 
glutamate signaling has been found disturbed [2]. Magnetic resonance spectroscopy studies have 
suggested that disturbances in glutamate may be opposite in mania and depression [92]. New 
research suggests that a disordered circadian system and sleep disturbances contribute to the 
symptomatology of BP [93].  
Neurodevelopment/altered neuroplasticity: Reduced brain volumes, reduced hippocampus, 
and reduced brain stem volumes have been found in BP [94]. Signs of reduced thalamus, nucleus 
accumbence and cerebellar cortex have also been presented [94].  
Immune related factors: There is no explicit immune hypothesis for BP, but the importance of 
immune related disturbances in the pathophysiology has been reviewed in recent years [95, 96]. 
There are fewer studies regarding immune related processes in BP than in SCH, and the main 
support for immune alterations in BP comes from studies regarding inflammation. (More 
information about this is presented in section 3.4.4 and 3.6.3).  
Two studies have also presented data regarding cognitive function and infection with HSV. They 
presented similar results as in SCH, i.e. that HSV was associated with poorer abilities on 
cognitive tests [97, 98]. There are few consistent studies regarding immunomodulating properties 
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of medication, but lithium and antidepressants have been reported to stimulate immune function 
and have anti-infective properties [99].  
4.4 Similarities between schizophrenia and bipolar disorders 
BP and SCH share many similarities and it may be difficult to differentiate the two disorders in 
the initial phases [100]. The diseases have overlapping risk genes, both patients groups are also 
vulnerable to stress. Prenatal infections have been found a risk factor of SCH, but is not 
documented in BP.  Both disorders have a peak of onset in early adulthood. The diseases also 
share symptoms as psychosis, cognitive impairments, depression and elevated risk of suicide. The 
disease course is often fluctuating with relapses and remissions in symptoms in both diseases. 
Both disorders may be treated with antipsychotics. Both diseases are also characterized by brain 
volume reductions in subcortical regions and of ventricular enlargements [94].  
4.5 The immune system 
The immune system is a wide term describing biological structures and processes that protects 
against disease and promotes survival [101]. The main tasks of the immune system are to identify 
and destroy pathogens, tumor cells and traumatized cells. Immunological competence in a host is 
a result of both genetic constitution and of the immunological experience acquired from previous 
infections and immunological challenges [102]. 
4.5.1 Innate and adaptive immunity 
The immune responses are divided into innate (natural) and adaptive (acquired). Adaptive 
responses are stimulated by specific properties of a pathogen which has infected the person. The 
adaptive response implicates that the immune system keep memory of previous challenges, so 
that it is able to react more rapid if this pathogen occurs again [103]. Adaptive responses are 
mainly mediated by lymphocytes, especially T- and B-lymphocytes. Adaptive  immune responses 
include those related to immunoglobulins (antibodies).  
It is the innate immune system which has been most investigated when it comes to the interaction 
between mental disorders and immunology [104]. This part of the immune system will be the 
focus in this thesis. Innate immune responses are non-specific and exist prior to exposure of 
specific pathogens. These kinds of responses react to molecules which are commonly found in 
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pathogens, as well as to common signs of traumas [103].  The innate immunity is mainly made up 
by  mechanical barriers as skin, intestines and the blood- brain barriers,  by immunological 
molecules in the serum and other bodily fluids, and by phagocytic cells as macrophages and 
neutrophils, which may engulf and eliminate pathogens and traumatized tissue [102]. 
The complement cascade is also a part of the innate immune system, and involves series of 
plasma proteins reacting in a cascade. The complement factors bind to pathogens and may induce 
destruction (lysis). The binding also attracts phagocytes and enhances elimination of pathogens. 
The innate immunity is also responsible for the immediate responses to traumas, including clot 
formation to stop bleeding. One mechanism is that complement increases the endothelial 
secretion of thrombosis promoting molecules [105].   
4.5.2 Major Histocompability Complex (MHC) 
A genetic region on chromosome six, called the Major Histocompability Complex (MHC), has 
central  immunological functions [102]. Among the most important genes are the Human 
Leucocyte Antigens (HLA). HLAs are expressed by virtually all cells, and are necessary for the 
recognition of the body’s own cells, in contrast to cells from foreign pathogens. In order to 
transplant an organ from one person to another, the HLA genes must be very similar, or else the 
immune system will destroy the new organ. HLA genes are involved in the pathology of many 
diseases, and have been associated with inflammatory diseases,  infections, autoimmune diseases, 
cancer, cardiovascular disases, brain diseases as well as with SCH [102, 106]. HLA have also 
been implicated in normal cognitive processes. It has, however, been difficult to find which of the 
specific genetic variants in the MHC region that are responsible for different diseases. This is due 
to a large number of exsisting variants, and  to that many of the genes in the MHC region are 
linked and inherited together [107]. 
4.5.3 Cytokines 
Cytokines are polypeptides secreted by cells, with key features of being pleiotropic (the ability to 
induce different biological responses in different cells)[102]. They are also paracrine (modulate 
their nearby cells by binding to receptors on their surface), autocrine (modulate the cells that 
secrete it), synergistic (act in concert with other cytokines to achieve greater effects than the 
summation of their individual ones), and endocrine (modulate cells and organs in other parts of 
the body). Cytokines typically first elicit a local effect, but as they spread and come into 
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circulation, they may affect other organs [102]. The liver cells typically respond to the cytokines 
by secreting acute phase proteins as C- reactive protein (CRP). The bone marrow typically reacts 
to the cytokines by increasing the release of neutrophil leukocytes. The fat and muscle cells 
respond by increasing their energy mobilization [102]. 
A large number of cytokines have been discovered. As the knowledge about them has increased, 
they have become markers of different pathological conditions [102]. Tumor necrosis factor 
alpha (TNF-α), Interleukin 1 beta (IL-1β) and Interleukin 6 (IL-6) are three central cytokines that 
have been extensively investigated. Although all cells may secrete cytokines, monocytes and 
macrophages tend to produce more of them than other cells [108]. 
4.5.4 Inflammation 
Inflammation literally meaning “to set on fire”, referred originally to the heat, redness, pain and 
swelling in infected body parts. Inflammation is a part of the innate immune response which 
serves to bring immune cells to the site of an infection or trauma, where they are needed to 
phagocyte damaged cells or pathogens and to start the repair process.  
The immune cells produce inflammatory signaling molecules including histamines, 
prostaglandins, leukotrienes and cytokines, to further promote the innate response[103].The 
complement cascade is also involved inflammation and serves to increases the defense against 
pathogens [109]. Endothelial cells of the vessels are highly involved in inflammation. They 
respond to inflammatory signals by expressing adhesion molecules, growth factors and other 
molecules that promote coagulation of the blood. By this, they restrict bleeding and spread of 
pathogens [110].  
In addition, platelets may contribute to the processes by excreting inflammatory mediators [111, 
112]. During inflammatory processes, the inflammatory molecules reach the circulating plasma. 
This is often referred to as systemic inflammation [113]. Molecules which restrict the 
inflammatory response are also necessary and are secreted during inflammation. They are called 
anti-inflammatory mediators. Both inflammatory mediators and anti-inflammatory mediators are 
often elevated in systemic inflammation. Both types may be assessed as markers of inflammation.  
Inflammation has been linked to behavior such as exercise, sleep, alcohol abuse, and smoking, as 
well as with medical conditions including coronary artery disease, obesity and insulin resistance, 
osteoporosis, pain, autoimmune diseases and cancer [96]. 
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4.5.5 Central inflammatory markers 
There is a range of inflammatory molecules. Some of the first discovered and most investigated 
are described here.  
4.5.5.1 Tumor necrosis factor alpha (TNF-α) 
TNF-α  is a general pleiotropic cytokine, involved with regulation of cellular life or death, and of 
synaptic integrity and ion homeostasis [114]. It has been described as having two main effects, a 
antiviral effect and an anti-cellular effect [115]. TNF-α mediates its effects through its two 
receptors, TNF-R1 and TNF-R2.  The TNF-R1 contains a so-called death domain [116] which 
implies the ability to signal that another cell should die through a process called apoptosis [103, 
117]. Apoptosis is an important immunological defense strategy [118] as it enables the killing of 
infected cells and of cancer cells [38, 46, 49, 116]. In some autoimmune diseases, TNF-α 
signaling is involved in destructive cell processes. Therefore TNF-α inhibitory medications is 
effective against autoimmune diseases as rheumatoid arthritis and ulcerative colitis [119].  
4.5.5.2 Interleukin 1–beta (IL1-β) 
The levels of IL1-β increases rapidly after a bacterial infection[120] and is also important for 
defense against viruses [121]. It has a major impact on autoimmune diseases. Therefore, 
antagonists of IL-1β have become widely used as medication for autoimmune diseases as 
psoriasis and rheumatoid arthritis. Although it is a central pleiotropic cytokine, with some similar 
effects as TNF, an increase in IL-1β in the brain, tends to downregulate peripheral levels of TNF-
α [122].  
4.5.5.3 Interleukin 6 (IL-6) 
IL- 6 is one of the earliest discovered cytokines, and has been intensively investigated. It 
increases in response to infections and is regarded a central inflammatory marker [123]. IL-6 is 
produced by working muscles and increase in response to physical challenges [124]. This 
increase in IL-6 has anti-inflammatory effects [125] which is in line with other studies reporting 
anti-inflammatory properties of IL-6 [126]. 
4.5.5.4 C-reactive protein (CRP) 
CRP was the first acute-phase protein described, and it is a well-known systemic marker of 
inflammation [127]. It increases more in response to a bacterial infection than a viral infection 
and therefore has become widely used to improve clinical diagnosis of infections [128]. While 
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virtually all cells may produce of IL-1, IL-6 and TNF-α, only the liver cells produce CRP. CRP 
binds to the surface of on pathogens promoting phagocytosis,  increasing the efficacy of 
phagocytosis of apoptotic cells [129]. It also activates the compliment system which further 
promotes phagocytosis [130]. High levels of CRP has been associated with atherosclerosis and 
cardiovascular disease [131]. IL-6 is a main inducer of CRP while TNF-α has been found to 
antagonize this stimulatory effect [132]. 
4.5.6 Other cytokines/inflammatory markers 
Interferon were discovered early, and has been much investigated [102]. They were  given their 
name because of their ability to interfere with viral replication, but has later also been found to 
increase in response to bacterial infections [103]. Interferon is divided into three main groups: 
interferon-α  mainly deriving from leukocytes, interferon-β mainly from fibroblasts and 
interferon gamma  mainly  from lymphocytes. Interferon has been used as treatment against 
multiple sclerosis, hepatitis C and cancer. This immune-modulating treatment may induce 
psychiatric side effects as irritability, mania, depression and psychotic symptoms [133, 134]. 
Many other cytokines have been [135] discovered. There are for example more than 35 classes of 
interleukins [102], and each interleukin may consist of several subtypes.  
4.6 The immune system and the brain 
Immunological responses may influence virtually every aspect of brain function relevant to 
mental function [136]. Several aspects of brain functions are influenced by immunological 
processes, both at the cellular level (synaptic plasticity, neuroendocrine function, 
neurotransmitter metabolism), and at the functional level (motor activity, fatigue, sleep, appetite, 
motivation, anxiety, mood and memory) [136]. However, the immune system in the brain is quite 
different from the rest of the body. The brain is protected from many antibodies by the blood 
brain barrier (BBB), and the brain is often called immunity-privileged.  The immune system also 
seems to play a separate role in basic neuronal functions which are not per se immune-related 
[135].  
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4.6.1 Immune cells in the brain 
The brain mainly consists of neurons and glial cells. Ordinary immune cells found in the rest of 
the body are not usually present in the brain. However, the brain glial cells have immunological 
properties. The microglial cells are the key innate immune cells of the brain. They survey the 
environment around the neurons and are specifically adapted to sense various types of danger and 
differentially react with reparative immune responses [137]. They are able to mediate immune 
processes between the peripheral immune system and the brain [138]. Astrocytes are the most 
abundant glia cell in the brain and they have the ability to express MHC class 2 molecules, which 
are mainly expressed by immune cells. They also express molecules and cytokines which are 
critical for immune cell activation [139]. The fact that glial cells have many typical immune cell 
characteristics may lead to high sensitivity to immune related signals, and expression of immune 
related molecules. A close interaction between brain and immunological processes may be the 
result. 
4.6.2 Immune molecules in neuroplasticity and brain development 
The last few years, intriguing links between neuronal processes and immune molecules have been 
discovered. Several  lines of evidence support that immune related molecules and inflammatory 
mediators are important for basic cognitive processes as learning and memory [135]. This was 
shown in a study that investigated molecules involved in the process of long-term memory 
consolidation. They found upregulation of the immune molecules MHC and Complement, while  
molecules involved in cell death signaling (apoptosis) were down regulated [140]. Several studies 
have also shown that central cytokines as IL-1β, IL-6 and TNF-α participate at the molecular 
level in cognitive functions, which has been described as a cytokine model for cognitive function 
[141]. The model describes how cytokines play intimate roles in the molecular and cellular 
mechanisms necessary for normal learning and memory processes [141]. Two mechanisms by 
which TNF-α  participates in memory processes, are by altering the expression of MHC 
molecules [135] and by regulating the strength of neuronal synapses in a process called synaptic 
scaling [142].   
Immune related molecules are also important for normal brain development. In line with this, 
elevated inflammation during pregnancy induces morphological abnormalities in the offspring. 
These abnormalities have been found to have similarities to those found in severe mental 
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disorders [143]. Furthermore, animals lacking cytokines as TNF-α or IL-1β do not develop 
proper memory function and show signs of neurodegeneration [144, 145].   
4.6.3 Blood brain barrier/ immune privilege  
The brain is protected from toxic molecules and infectious agents by the BBB, a tight membrane 
through which large molecules normally cannot pass [146]. Therefore, usually compounds in 
serum cannot be assumed to have the same concentration in the brain. The immune responses in 
the brain are also more restricted. This phenomenon is thought to be adaptive as it secures the 
preservation of neurons. It is generally better that the immune system accepts a low virulent 
infection than to kill a neuron [147]. The restricted immunological response may be beneficial for 
pathogens, and is called the immune privilege. Although the BBB protects the brain from 
peripheral molecules, recent data have shown that peripheral cytokines can cross the intact BBB 
[147, 148].  
 
4.6.4 Brain /body immune communication  
When the brain perceives psychological challenges or psychological stress, it may influence the 
immune system through signaling through autonomic nerves. These nerves go directly from the 
brain to the spleen, which is a major immune organ. The brain processes also influence immune 
processes through nerves to the adrenal glands, which secretes stress hormones as adrenalin, 
which again has immune suppressive effects [149]. Cortisol is another stress hormone with anti-
inflammatory effects [150]. However, the effect of stress on immunological responses is 
complicated, and may not always be suppressive. Mental stress may also lead to aggravated 
inflammatory responses [151]. During peripheral infections, the cytokines have been found to 
mediate several effects in the brain [152]. They  typically induce sleepiness, loss of appetite, 
increased fatigue, more pain, poorer cognition and negative feelings [153]. 
4.6.5 Inflammation and cognitive impairment  
High levels of systemic inflammation have been found to have negative impact on cognitive 
function in both animal and human studies [154].  In conditions under which the immune system 
is strongly activated by infection, injury, or other stressful conditions, the brain glia cells change 
their function and secrete high levels of inflammatory mediators [154].  This secretion disrupts 
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the balance of immune molecules needed in cognitive processes, and it induces detrimental 
effects on memory, neural plasticity and neurogenesis [154]. In line with this, high inflammation, 
as assessed by TNF-α, is present in neurodegenerative diseases such as ischemic stroke, 
Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, and multiple sclerosis [155]. High levels 
of inflammation are also associated with poorer cognitive function in healthy persons. The largest 
study so far, including 49.000 healthy men, found that low-grade inflammation was associated 
with reduced cognitive abilities at the age  of 18-20  years [156]. Another study in 447 healthy 
persons found that low-grade inflammation was associated with disintegration of brain structures 
seen on brain imaging, as well as with reduced cognitive function [157].  In line with these 
results, a study of 691 healthy persons, found that those who had high inflammation, had 
increased risk of cognitive decline into dementia during the next years [158].  
 
4.6.6 Neurotropic pathogens 
A pathogen is called neurotropic if it is capable of infecting neurons, and does so preferentially 
[103]. Common neurotropic pathogens are HSV, Varicella-Zoster, Cytomegalovirus, Epstein-
Barr,  Mumps, Measles, Influenza, Coxsachie, Echo, Rabies, Encephalitis viruses and Borrelia 
burgdorferi [159, 160]. Herpes simplex virus 2 (HSV2) is the most common cause of brain 
infection in fetal life and new-born children, and usually results in  selective impairments in 
cognitive function [161].  After the neonatal period, HSV1 is the most common viral brain 
infection (encephalitis). Toxoplasma gondii infects approximately 30% of the population, but 
causes overt clinical symptoms in only a small proportion. During chronic infection, Toxoplasma 
forms cysts which are located in the brain. The parasite has the ability to manipulate behaviour of 
infected animals and Toxoplasma has two enzymes which potentially could affect dopamine and 
serotonin transmission [162].  
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5 Specific research questions in this thesis 
5.1 How is the inflammatory profile in serum of schizophrenia and bipolar 
disorder patients? 
It has been suggested for more than fifteen years that inflammation may play a role in the 
pathology of SCH, and it has been investigated with inconsistent results. A study from 1995 
reported that patients did not have elevated levels of TNF-α, IL-6 or IL-1β [163]. Also in 1999 
and  2001 studies reported that there were no evidence of elevated cytokines [164]. However, in 
summer 2007, when the work this thesis started, 62 studies regarding cytokines and SCH had 
been published [165]. According to a meta-analysis, which was published in 2008,  there was 
evidence of elevated activity in the IL-1Ra sIL-2R and IL-6 [165]. In SCH, there were fewer 
studies, and most had investigated bipolar mania [166]. The first study investigating both 
depressed and manic patients was published in 2006, and had included 8 bipolar depressed 
patients [166]. According to a review published in 2009, six studies have compared inflammatory 
markers in serum of BP patients, independent of affective state. Four of these have found  low 
levels and two elevated levels compared to controls [167]. However, these previous studies are 
small and the number of inflammatory parameters investigated in the same study are limited. For 
example, the general marker CRP has not been measured together with other inflammatory 
markers [167]. This makes it difficult to draw conclusions about degree and type of inflammatoy 
disturbances [167].  
High levels of inflammation is associated with cardiovascular disease (CVD). The most 
investigated inflammatory marker with respect to CVD is CRP [102]. However, also other 
general inflammatory markers, TNF, IL-6 and IL-1β have been reported to be risk factors of 
CVD [168, 169]. It is therefore possible that these markers are related to the high cardiovascular 
comorbidity in patients [167].    
Inflammatory pathways are closely interacting with coagulatory pathways, and the 
endothelial cells are an important interface for the interaction [110, 111]. Von Willebrand factor 
(vWf) is a typical endothelial related factor related to both coagulation and inflammation[102]. 
Endothelial cells form structural basis for the BBB, and the endothelial related vWf  influences 
this barrier. In cases of systemic inflammation vWf  increases the inflammatory processes within 
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the brain [170].  vWf  has also been associated with increased mortality [171]. These 
characteristics make vWf an interesting factor when investigating inflammation in severe mental 
disorders.  
 Inflammatory markers are also closely related to platelet derived coagulation mediators. 
CD40L is a platelet related marker which is associated with increased risk of CVD, although 
investigated in few studies [172, 173].  CD40L has been found elevated  in different forms of 
dementia, which supports that it may be involved in the pathology of neuropsychiatric disorders 
[174]. Whether levels of CD40L are elevated in severe mental disorders has not been 
investigated.  
  Although there is some evidence of high levels of the same inflammatory mediators 
(TNF, IL-1β and IL-6) in both BP and SCH [108], it is not known whether the elevations are  
more pronounced in one of the disorders. Infections in early life increase risk of SCH, but are not 
associated with increased risk of BP. This difference could be hypothesized to be caused by 
different degree of immune disturbance. However, no previous studies have compared 
inflammatory markers in SCH with BP, and thus it is not known if there are differences in their 
inflammatory serum profiles.  
To summarize, several lines of evidence suggest immune disturbances to be of importance 
in the pathology of severe mental disorders and cardiovascular disease. Inflammatory markers 
have been investigated in small studies, and have suggested elevated levels of some inflammatory 
markers, although with somewhat inconsistent findings. No previous studies have investigated 
whether endothelial related or platelet related inflammatory factors are elevated. Furthermore, it 
is unknown whether there are differences in the inflammatory profile of SCH and bipolar 
disorder.  
5.2 Is Osteoprotegerin elevated in severe mental disorders? 
Calcium-related disturbances have been reported in BP and SCH, although the number of studies 
is limited [175-178]. That calcium  may play a central role in the pathology is supported by that 
lithium interferes with calcium pathways [179]. Calcium has also been associated with genetic 
vulnerability as variants in the calcium channel CACNA1c is one of the top susceptibility genes 
[180].  Furthermore, a proteome analysis of SCH brains found that calcium and immune related 
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molecules were the most disturbed ones [181]. Calcium has  been found to have immune 
stimulatory effect [182], and thus it may be hypothesized that calcium is involved in immune 
related pathology of severe mental disorders. However, this has not been investigated earlier.    
Osteoprotegerin (OPG) is a marker found to reflect calcium-related inflammatory 
disturbances [183]. The marker acts as a decoy receptor for a genetic transcription factor called 
Nuclear factor kappa B (NF-ĸB ) [184]. NF-ĸB has been much investigated and medications 
targeting NF-ĸB  and OPG  have already been developed [185]. NF-ĸB is encoding central 
immune regulatory genes. It has also been found to be involved with regulation of excitatory 
neurotransmission [186]. Mood-stabilizing medication have impact on NF-ĸB , and thus it could 
be speculated that this is of importance for their treatment effect [187]. OPG has also been much 
more  investigated in the pathology of somatic diseases, than in psychiatric, and it has been found 
to be a risk factor of atherosclerosis and CVD [184]. OPG’s relation to calcium disturbances, 
neurotransmission and CVD makes it possible that it is of importance in the pathology of severe 
mental disorders.  As it is a new inflammatory marker not previously measured in severe mental 
disorders, it was investigated thoroughly in a separate study. 
5.3 Are levels of inflammatory markers associated with affective state? 
Despite the emergence of a more reproducible pattern of elevated systemic inflammation in BP, 
the results from different studies are inconsistent [188]. A key feature of BP is the large variation 
in mood: Periods with high spirits, high energy and reduced need for sleep, then shift to 
depressed mood reduced energy and increased need for sleep. Symptoms as increased sleep, 
reduced energy and mood are also commonly seen in conditions with high levels of inflammatory 
mediators [189]. Therefore, it has been hypothesized that inflammation may be contributing to 
pathology of depression. In addition, according to a recent review of research, it is evidence of 
high levels of the inflammatory markers TNF-α and IL-6 in unipolar depression.  
However, there is no evidence of high IL-1β or interferon. On the contrary, the mean 
levels in depressed patients of those markers were non-significantly lower than in controls [190]. 
Another review recently showed that depression seems characterized by both immune 
suppression and activation. It has also been speculated whether shifts in inflammation may 
induce a shift in affective state. A  study of healthy volunteers showed that after an immune 
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challenge with increased levels of inflammation, a normalization of inflammatory markers was 
associated with elevations in mood [191].   
Most previous studies in BP have investigated inflammation in manic state [166]. In 
2008, seven studies had measured inflammatory markers in patients with mania. All of them 
reported that some of the inflammatory markers were elevated [192-200]. Up to 2009, four 
studies had found elevated levels of inflammation, two had found normal levels [192, 197-201], 
and one study had found that some markers had an inverse pattern in manic versus depressive 
state [200].  As the studies in bipolar depression are inconsistent, and are heterogeneous in 
sample compositions, cytokine assessments, treatment regimens and ethnic groups, it was 
difficult to compare results from the different studies [96]. It was a lack of studies comparing 
levels of inflammation in mania, depression, and neutral affective state, with inflammation in 
healthy volunteers would help interpret results [96]. A study investigating if inflammation is 
associated with severity of mood symptoms, would also be of importance, as no studies so far has 
reported any significant associations [96].  
Inflammation has been associated with mood symptoms in different diagnostic categories as 
unipolar depression and mania. BP share some similarities with SCH, Mood symptoms are 
prevalent in both disorders [2, 6, 202]. However, how inflammation relates to mood symptoms in 
SCH patients is not known. It could be hypothesized that mood symptoms will be associated with 
inflammation in a similar way across diagnostic boundaries. However, it is also possible that 
inflammatory mediators are involved in the core pathology of affective dysregulation of BPs, 
while not involved in mood symptoms in SCH. This has, however, not been investigated in any 
study.  
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6 Aims 
The overall aim was to gain more knowledge about the role of inflammation in severe mental 
disorders. 
The sub aims were:  
1- To determine if patients with severe mental disorder have elevated inflammation 
compared to healthy controls, and to identify any specific inflammatory pathways that 
may be disturbed. 
2- To evaluate if the inflammatory profile was different in patients with BP compared to 
those with SCH. 
3- To determine if levels of OPG were different in patients with SCH and BP compared to 
healthy controls, and in SCH compared to BP.  
4- To examine if inflammatory markers were associated with affective state.  
 
 
7 Methods 
7.1 Subjects   
Patients: The study was carried out in the catchment area of the University Hospitals of Oslo, 
Norway, including patients from both inpatient and outpatient treatment units. The patients were 
included through referrals by clinicians working in the treatment units. The inclusion criteria 
were known in the psychiatric services of the participating hospitals. The age of the patients was 
between 18 and 65 years. They had DSM-IV criteria for SCH or BP spectrum disorders, and were 
willing and able to give written, informed consent of participation. Exclusion criteria were history 
of moderate or severe head injury, neurological disorder and mental retardation (IQ less than 70).  
In the first study patients with autoimmune disorders, use of non-steroid anti-
inflammatory drugs or statins were excluded. In the second and third studies, patients with 
autoimmune diseases were included, increasing the representativeness of the sample. In these 
studies, results were controlled for differences in autoimmune diseases. In the second and third 
studies, only those who had both adequate blood measurement of both inflammatory markers and 
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confounding factors were included. In the first study, there were 311 patients. In the second 
study, the number was 312. In the third study, 36 fewer patients participated.  
Of the 312 patients, 186 (185 in study 1) had a DSM-IV schizophrenia spectrum disorder: 
(Schizophrenia [n=143], Schizophreniform [n=11] and Schizoaffective disorder [n=33]). 125 had 
a bipolar spectrum disorder (Bipolar I disorder [n=73], Bipolar II disorder [n=44] and Bipolar not 
otherwise specified [n=8]). In the third study, there were 22 fewer SCH patients and 14 fewer BP 
patients due to more strict inclusion criteria regarding affective symptom measures. One more 
SCH patient was included due to access to new clinical data. The samples in the third study were 
compared with the samples in study one. The inflammatory marker levels and the clinical and 
sociodemographic characteristics were not significantly different. 
7.2 Controls  
A representative control group of 244 healthy volunteers was randomly selected from 
statistical records in the same catchment area as the patient groups. They were contacted by letter 
inviting them to participate. Included were controls without a history of medical problems, severe 
psychiatric disorders including alcohol or illicit substance abuse/dependency, or severe mental 
disorder in close relatives. In study number two and three, there were five fewer controls, as only 
participants who had both successful measurements of inflammatory and confounding factors 
were included.  
 
7.3 Selection of inflammatory markers 
It was focused on four central and general inflammatory pathways which previous smaller studies 
have suggested to be involved in severe mental disorders. In addition to these central markers, 
three new markers of distinct inflammatory pathways were examined, to find out whether 
patients had any specific inflammatory disturbances. High frequency of cardiovascular disease is 
seen in severe mental disorders, and inflammatory markers involved in pathology of 
cardiovascular diseases were therefore also selected. 
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Tumor necrosis factor receptor type 1 (TNF-R1): TNF-α is a general inflammatory marker 
which has been found elevated in previous studies. However, it has a short half-life and low 
reliability in serum-measurements [203]. TNF’s effect is based on binding to its two receptors, 
TNF-R1 or TNF-R2 [204]. High serum levels of TNF-α induce an elevation of these two 
receptors. Usually the levels of TNF-α and TNF- receptors are highly correlated [205, 206].  
Furthermore, the TNF-α receptors stabilize TNF-α’s structure and preserve its activity [207]. 
Therefore the receptors are reliable indicators of TNF-α  activity [207]. TNF-R1 is the major 
TNF-α receptor in serum [208]. It is stable in serum measurements and has higher accuracy with 
regard to the follow-up and prognosis of various diseases than TNF-α [209, 210]. Also in SCH, a 
previous study found elevated levels of sTNFR1, but no difference in TNF-α [211]. Therefore we 
chose to measure TNF-R1. 
 
Interleukin 1 receptor antagonist (IL-1Ra): IL-1β is a general inflammatory marker, but this 
marker often circulate in a concentration below detection limit [212]. IL-β exerts its effect 
through different receptors, and the receptors increase in cases of inflammation [213, 214]. This 
means that although IL-Ra has antagonizing effects on IL-1β when given as treatment, the IL-
1Ra is increased in serum of patients with high IL-1β. IL-1Ra is a receptor for IL-1β which has 
been found to have reliable properties in serum measurements [209]. Furthermore, IL-1Ra has 
been found elevated in previous studies of mental illness [165] and therefore we chose to measure 
this marker.  
Interleukin 6 (IL-6): IL-6 is a central inflammatory marker, and this marker has been suggested 
to be included in all further studies of cytokine induced sickness behaviour [215]. Therefore this 
marker was included.  
 
C-reactive protein (CRP): This is the prototypical inflammatory marker widely used in 
diagnosis of bacterial infections [128]. Contrary to the three previous general markers, it is 
produced in the liver. High sensitive CRP (hsCRP) is the inflammatory marker which has been 
most investigated as a marker of cardiovascular risk [131], and therefore this  marker was 
included.  
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Von Willebrand factor (vWf): Von Willebrand factor (vWf) is an endothelial related 
inflammatory marker [216], important for proper hemostasis and coagulation [217].  
vWf  influences the blood brain barrier and  induces brain inflammation in models of 
encephalomyelitis [170]. A lack of vWf results in bleeding disorders [218],  while high levels is 
associated with thrombosis [219]. VWf has not been measured in severe mental disorders, and 
therefore we selected this marker.  
CD40 ligand (sCD40L): The soluble form of CD40L (sCD40L) is derived mainly from activated 
platelets [220], which makes this a good marker of platelet related inflammation. CD40L is 
associated with cardiovascular diseases [221], with dementia and with marked depression [222-
224]. Levels of sCD40L have never been measured in severe mental disorders, and therefore this 
marker was selected. 
Osteoprotegerin (OPG): As described in section 3.6.2, OPG  is a novel inflammatory marker 
reflecting activity in the central inflammatory transcription factor NF-ĸB. OPG circulates at much 
higher levels than the receptor activator of NF-ĸB (RANK) it has been found to be a stable 
measure of RANK/RANK ligand activity [184]. As it is a new marker and calcium related genes 
are susceptibility genes for severe mental disorders, OPG was investigated more thoroughly in a 
separate study.  
 
7.4 Design 
The study was organized through the multicenter study called “Tematisk Område Psykose” 
(Thematically Organized Psychosis (TOP) Study). TOP was initiated at Oslo University Hospital, 
Ullevaal, in 2002. Later, the catchment area of the study has been extended, and researchers from 
several other hospitals in Norway have joined the study group. The TOP study is approved by the 
Regional Committee for Medical Research Ethics (2009/2485) and by the Norwegian Data 
Inspectorate(2003/2052). The biobank is approved by the Norwegian Directorate of Health 
(200403453). The catchment area includes Oslo and surrounding areas. It includes approximately 
one million inhabitants. The current study is naturalistic, cross sectional involving group 
comparisons. 
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7.5 Clinical Assessments 
The assessments were conducted by psychologists or MDs, with specific clinical psychiatric 
training. The assessments generally took place over two sessions including a diagnostic 
interview, assessment of symptoms, a physical examination and a blood withdrawal. Patients had 
a physical examination at the day of the blood sampling and were free of infections, supported by 
hsCRP below 20 ng/ml, and were stable, not in an acute phase.  
 
7.5.1 Diagnostic interview and clinical characteristics 
The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) was used for diagnostic 
purposes.  Inter-rater reliability was good, with an overall kappa score of 0.77 (95% C.I: 0.60-
0.94) for diagnoses. Global assessment of symptom severity and functioning was measured with 
the Global assessment of functioning (GAF) Scale (split version). The intra class correlation 
coefficient, one-way random single measures (ICC 1.1), were 0.86 for both symptom and 
function GAF scores. The Structured Positive and Negative Syndrome Scale (SCI-PANSS) was 
also used, and total scores were recorded to indicate general symptom severity [225]. Information 
about age, gender and ethnicity were recorded. Ongoing medication with mood stabilizers, 
lithium, antipsychotics or antidepressants and of somatic medication was also noted. Smoking 
habits, the intake of alcohol (number of alcohol units) and the use of illegal substances (number 
of times) the last two weeks was registered.  Furthermore, medical history was noted, especially 
if they had diagnosis of diabetes, cardiovascular or autoimmune disease, as well as height and 
weight for body mass index calculation. 
7.5.2 Mood assessment 
The severity of manic symptoms was measured with Young Mania Rating Scale (YMRS) [226] 
and depression with Inventory of Depressive Symptomatology (IDS) [227], and a SCH subgroup 
was only evaluated with Calgary Depression Scale for Schizophrenia (CDSS) [228].  
In study III, three affective state groups were defined. The groups were based on validated cut off 
scores for mania on the YMRS, and on validated cut off scores for depression on IDS, together 
with an evaluation of the core symptoms of mania and depression.  
“Neutral” mood group was defined as total score on YMRS < 8, and the core item elevated mood 
= 0. In addition, total score on IDS < 14 and core item sad mood = 0.  
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“Elevated” mood group was defined as total score on YMRS > 7 or the core item elevated mood 
> 1. “Depressed” group was defined as total score on IDS > 14 or core item sad mood >one.  
In 37 SCH patients and 4 BP patients the depressive symptoms had only evaluated with CDSS 
[228]. This scale has similar to IDS a core item for sad mood, “depressed mood” that consists of 
4 levels, and the total CDSS cut-off score for depression is 7 [229].  
In patients evaluated with CDSS  “Neutral” was defined as a score of 0 on core item “depressed 
mood ”  together with a total score on CDSS <7, and “Depressed” was defined as core item sad 
mood > 1 or CDSS total score >7. Patients who had a score >1 on both core item elevated mood 
on YMRS as well as core item sad on IDS/CDSS or had missing for one of the scales were 
classified as “Mixed group”. This group consisted of 11 BP and four SCH patients and was not 
included in the analysis of affective states, only in the correlation analysis of affective symptom 
levels.  
7.6 Laboratory analyses 
The blood was drawn between 8am and 5pm, and the time for the blood sampling was recorded. 
The time difference between blood sampling and clinical assessment was also recorded. 
 
Plasma levels of sTNF-RI, IL-1Ra, CD40L, IL-6 and OPG were measured by enzyme 
immunoassays (EIA) obtained from R&D Systems (Minneapolis, MN, USA). Plasma 
concentrations of vWf were measured by EIAs using antibodies from DakoCytomation (Norway) 
as described by Bollerslev [230]. Levels are given in plasma concentration percent (%). The 
standard curve is based on samples from a plasma pool of healthy individuals, were the normal 
range is arbitrary set to 70-130%. All intra- and inter-assay coefficients of variance were <11%.  
 
Blood samples were analyzed regarding kidney function (creatinine), liver function (alanine 
aminotransferase; ALAT) and dyslipidemia (cholesterol and triglycerides) and glucose levels. 
These clinical blood sample analyses (hsCRP, creatinine, alanine aminotransferase; ALAT, 
cholesterol, triglycerides, glucose) were performed according to standard procedures at 
Department of Clinical Chemistry, Oslo University Hospital, Oslo, Norway. 
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8 Statistics 
8.1 Statistical tests 
All Statistical analyses were done using the SPSS Software package for Windows, version 15.0 
(SPSS, Chicago, IL, USA). All tests are two-sided with a preset level of significance of 0.05.  
 
Four markers (IL-1Ra, hsCRP and IL-6 and CD40) were significantly skewed. In the first study 
these markers, as well as TNF-R1 and vWf were analyzed with nonparametric tests. Spearman’s 
Rho was used for correlation analysis and Kruskal–Wallis test for comparisons with three groups. 
Mann–Whitney U-test was used for post-hoc analyses. The latter was corrected for multiple 
testing through Bonferroni correction. 
OPG values were normally distributed and students T-tests were used to compare the patient 
group with the controls. To test if the variance differed between the groups, Levene test for 
equality of variances was used. Differences in the level of OPG across the two diagnostic groups 
together with the controls were analyzed by use of a 1-way analysis of variance (ANOVA) with a 
Tamhane’s post-hoc correction. 
 
In study III, markers that were not normally distributed were logarithmically transformed in order 
to obtain normal distribution. It was first analyzed if there were different levels of immune 
factors in different affective state groups, by doing ANOVA with a three level model (depressed 
= 0, neutral = 1, and elevated =2). As post-hoc test Tamhane’s test was used, which is a test 
based on unequal variances in the groups. Students T-tests were used to compare affective groups 
with controls. It was also analyzed if there were group differences with ANOVA, giving the same 
results (analysis not presented in the study)   
To investigate if levels of immune factors were correlated with severity of depression or mania, 
Pearson’s correlations test was used. These analyses were done separately for BP and SCH. 
To find out how much of the variance in one inflammatory marker that was explained by the 
other markers, linear regression was used. The marker was put as dependent into a linear 
regression analysis, with all the other markers as independent variables.  The R square for the 
total model was calculated to find how much of the variance that was explained by the other 
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markers.  
8.2 Analysis of correlations between the inflammatory markers 
Cytokines share many properties and have diverse effects. It was possible that the different 
inflammatory markers were highly correlated. If so, it would be uncertain if the markers 
represented specific inflammatory pathways. Therefore, correlation analysis between the markers 
was done.  
In the first study, correlation analysis between the inflammatory markers, measured with the non-
parametric Spearman’s Rho test was done. In the total sample, STNF-R1 was the only marker 
that correlated significantly with all other markers, with highest r-value for vWf (r= 0.28) and the 
lowest for hsCRP(r=0.2) (p < 0.00001). In addition to TNF-R1, VWF correlated only with IL-
1Ra (r = 0.15, p < 0.0005). The strongest correlation was seen between IL-6 and hs-CRP (r = 
0.48, p < 0.00001).  
Smoking habits among the patients did not significantly correlate with sTNF-RI, vWf, or hs-
CRP.  The inflammatory cytokines were not correlated to the cortisol levels in patients, except for 
hs-CRP, which had a small positive Pearson correlation coefficient with cortisol of 0.12 (p = 
0.04). 
In study III, in the total sample of patients and controls, Pierson’s correlations were used to test 
correlations between inflammatory markers. The analysis showed that sTNF-R1 and Log 
transformed IL-1Ra had the strongest correlation (n=503, r= 0.40, p<0.001), OPG and IL-6 had 
the weakest (n=503, r=0.10, p=0.02) while IL-1Ra and hsCRP were not significantly correlated 
(n=498, r=0.06, p=0.17). The combined effect of other inflammatory markers explained 25 % of 
the variance in sTNF-R1, 11 % of the variance in vWf, and 8% of the variance in OPG, 15% of 
IL-6, 14% of hsCRP and 14% of CD40L.  
In study III, there were significant correlations between the mood measures. Total score on IDS 
in BP patients was highly correlated with sad mood (n= 222, r=0.78, p<0.001) while total score 
on YMRS was moderately correlated with elevated mood (n=265, r=0.39, p<0.001). Total YMRS 
was only moderately negatively correlated with total IDS score (n=222, r=-0.24, p<0.001). When 
two inflammatory markers were correlated with the same mood symptom measure, a regression 
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analysis was done to investigate if the markers were independently correlated with degree of 
mood symptoms. 
8.3 Control for possible confounding factors: 
8.3.1 Confounders, study I and II 
To control for differences in factors which could have been differently distributed between 
patients and controls, hierarchical multiple linear regression analyses were used. The possible 
confounding factors were added as independent variables into a regression analysis for predicting 
levels of the inflammatory markers. The BP and SCH patients were gathered in one group, and a 
variable of patients versus controls was entered into the linear regression as the last step.  
In study II, the linear regression did not include cortisol levels or time at blood sampling due to 
lack of complete information in all subjects. 
 
8.3.2 Confounders, study III 
The study investigated differences in smaller groups of patients, and wanted to control for many 
possible confounding factors. It is recommended to have ten times higher number of cases than 
independent factors in a linear regression sample, and not all independents could be included into 
the same regression analysis. An evaluation of which factors that most likely could confound the 
results was done. 
A factor may confound an association between inflammation and affective groups only if it is 
correlated with an inflammatory marker and is differently distributed between the groups. 
Therefore, it was first analyzed if there were any differences in the distribution of possible 
confounding factors between the three affective groups or between affective groups and controls 
by performing ANOVA. All differently distributed factors and factors that were bivareately 
correlated with immune markers were than analyzed together with ANCOVA to see if they had a 
combined effect on immune markers.  
To control confounding factors in the correlation between immune markers and mood symptoms 
a bivariate correlation analysis investigated associations between the confounding factors, 
immune markers and mood symptoms. The combined effect of all possible confounders that were 
significantly correlated with either mood symptoms or immune markers was controlled with a 
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linear regression analysis. In addition, models including factors which were not correlated with 
either mood symptom or the immune markers were put into the regression model, without having 
any significant impact.  
 
 
9 Results 
9.1 Study I 
9.1.1 Are inflammatory markers elevated in severe mental disorder? 
The combined patient group had highly, statistically significantly elevated levels of two 
inflammatory markers: sTNF-RI and vWf compared to the healthy control group, (p<0.000002 
for both) (Table 2). The increase was 17 % for sTNF-RI and 27 % for vWf (Table 2, Study I). In 
contrast, there was no significant difference in the levels of IL-6, sCD40L or IL-1Ra between the 
patients and the controls, but hs-CRP was significantly elevated (p=0.02). Also in unmedicated 
patients there was a significant increase in plasma levels of sTNF-R1 (1.09 versus 0.91 ng/ml, 
p<0.001) and vWf (101 versus 77 %, p<0.007) as compared with concentrations in healthy 
controls.  
These elevations remained significant also after controlling for possible confounders. There were 
no significant differences in any inflammatory parameters between medicated and unmedicated 
patients. 
 
Limiting the analysis to patients with strict SCH and BP I (i.e. excluding patients with 
Schizoaffective, Schizophreniform, Bipolar disorder II, and Bipolar disorder not otherwise 
specified), the immune profile was still similar and the elevations remained statistically 
significant (data not shown).  
 
As seen in table 2 of study I, there was a trend that SCH patients had higher levels of IL-1β than 
controls, but the difference was not significant. However, since there are indications of diurnal 
variation in inflammatory markers [231], it was analyzed whether there were correlations 
between timing of blood sampling and inflammatory markers. None of the markers were 
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correlated with timing except from IL-1Ra (r=0.13 - 0.14, p=0.03 – 0.06). Therefore, the levels of 
IL-1Ra in patients and in strictly time-matched controls were compared. It was found that 
patients had higher levels than these time matched controls (p= 0.007). However, when this result 
was controlled for possible confounders, the difference was not significant (p=0.17).   
 
9.1.2 Do schizophrenia and bipolar disorder have similar immune profile? 
There were no significant differences in levels of any inflammation markers between the two 
diagnostic groups. When each diagnostic group were compared to controls, they both showed 
highly significant elevations of sTNF-RI (p < 0.001) and vWf (P < 0.005) (Table 2, Study I). A 
difference in hs-CRP levels did not remain significant when the patient group was divided into 
SCH and BP, probably due to loss of statistical power.  
 
9.2 Study II 
9.2.1  Do patients have elevated levels of osteoprotegerin? 
OPG levels in patients and controls are shown in table 2, study II. The mean OPG level was 10% 
higher in the patient group (MeanSD; 2.78 1.47 ng/ml) than in the controls (2.52 0.92 ng/ml; 
t=2.6, DF=531, p= 0.01). The comparison of OPG levels across the groups (SCH, BPs, and 
healthy controls) indicated a significant between-group difference (F=3.1; def. =550; p=0.046) 
(Table 2, study II). None of these group differences, however, reached the level of statistical 
significance after corrections for multiple testing (BP vs. controls: p=0.08, SCH vs. controls: 
p=0.20 and SCH vs. BP: p=0.94).  
A regression analyses showed that OPG levels were significantly elevated in the patient group as 
a whole compared to the controls also after controlling for 11 different factors that possibly could 
have confounded the result  (t=-1.97, d.f.=485, p=0.049) (Table 3, Study II).  There were slightly 
more women among the controls (56%) than the patients (50%). Women also had higher OPG 
(2.841.35) than men (2.481.14) (p=0.001), but in the overall sample the group x gender 
interaction term was not significant (p = 0.35). 
There were some differences between the diagnostic subgroups, were schizoaffective disorder 
and bipolar disorder type II had the highest levels. However, the differences did not reach 
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statistical significance: SCH (n=143) 2.721.36; Schizophreniform (n=11) 2.25 0.67; 
Schizoaffective disorder (n=33) 3.04 2.13; Bipolar I disorder (n=72) 2.760.05; Bipolar NOS 
(n=8) 2.22 0.34; Bipolar II disorder (n=45) 3.060.92. Within the patient group as a whole, 
OPG was positively correlated with age (r=0.15, p<0.001) and female gender (r=0.15, p<0.001). 
OPG was positively correlated with cholesterol and hsCRP (cholesterol: r=0.14; hsCRP: 
r=0.17, p<0.001).  OPG was weakly negatively correlated to creatinine (r=-0.09, p=0.04). There 
were no significant correlations between OPG levels and BMI (r= 0.03, p= 0.6). OPG levels in 
239 non-obese subjects (BMI < 30) had BMI of mean ±SD 24.1 ± 3.26 kg/m2  were also 
significantly higher compared with controls (2.79 ± 1.5; versus 2.52 ± 0.92; t=2.3, d.f. =391, p = 
0.021).  OPG was still significantly elevated in patients versus controls also after control for 
glucose and cholesterol, which are traditional risk factors of metabolic syndrome.  
Patients not treated with antipsychotics (n=80) had significantly higher OPG than controls (mean 
±SD 2.93±1.41 ng/ml vs. 2.52±0.92 ng/ml; t=2.4, d.f. =102, p=0.02). In addition, there was no 
difference in mean OPG between the patients using first and second generation antipsychotics 
(first generation antipsychotic: n=19 [OPG 2.64±0.89 ng/ml] and second-generation 
antipsychotics; n=242 [OPG 2.78±1.50 ng/ml; t=-0.44, d.f. = 259, p=0.6]). The analyses suggest 
that medication did not confound the results.  
9.3 Study III 
9.3.1 Are markers of inflammation associated with different affective states? 
As seen in Table 2, study III, the levels of all inflammatory markers were lowest in the depressed 
group of BP. All markers were higher in the Elevated mood group than in the Depressed group. 
Neutral mood group had intermediate levels of four markers, and highest levels of markers IL-6 
and hsCRP. There were significant differences across affective groups. sTNF-R1 and IL-1Ra 
differed significantly in Depressed vs. Elevated (p= 0.007 and p=0.04 respectively), OPG and IL-
6 differed significantly in Depressed vs. Neutral,(p=0.04 and p=0.01 respectively).  
There were no significant differences in vWf or hsCRP across affective state groups. There was a 
tendency of increasing levels of inflammatory markers with increasing affective state groups that 
was significant with respect to sTNF-R1 (r=0.29, p=0.003), OPG (r=0.29, p=0.003), IL-1Ra 
44 
 
(r=0.28, p=0.005) and IL-6 (r=0.21, p=0.04). In SCH there were no significant differences across 
affective state groups and no trend of higher levels in Elevated state group (see Table 2, study III.   
9.3.1.1 Inflammation in controls vs. different affective states 
Bipolar disorder patients in Elevated mood group had significantly higher levels than controls of 
four markers, and the difference was significant for sTNF-R1 and vWf (p=0.000005 and p= 
0.002 respectively). Patients in Neutral mood group had higher levels of all markers compared to 
controls, and the difference was significant with respect to OPG and IL-6 (p=0.0003 and p=0.005 
respectively). BP patients in Depressed mood group had approximately equal levels as controls, 
i.e. non-significantly higher levels of TNF-R1, vWf and hsCRP and non-significantly lower 
levels of OPG, IL-1Ra and IL-6.  
SCH patients in Depressed mood group, had higher levels than controls of TNF-R1 and vWf 
(p=0.0001 and p=0.008 respectively). Patients in Neutral mood group had higher levels than 
controls of vWf (p=0.02) and patients in Elevated mood group had higher levels of hsCRP than 
controls (p=0.03).  
9.3.1.2 Severity of affective symptoms in relation to levels of inflammatory markers: 
The severity of depressive symptoms as measured as total IDS score was significantly negatively 
correlated to three cytokines:  OPG (n=107, r= -0.27, p=0.005), IL-1Ra (n=107, r=-0.30, 
p=0.002) and IL-6 (n=107 r=-0.27, p=0.006). Severity of the core depressive symptom “sad 
mood” was also significantly and inversely correlated with these cytokines: OPG (n=111, r=-
0.34, p=0.0003), IL-1Ra (n=111. r=-0.31, p=0.001) and IL-6 (n=111 r=-0.35, p=0.0002). 
Regression analysis showed that OPG and IL-1Ra were independently correlated with total IDS, 
and that OPG and IL-6 were independently correlated with depressed mood. The other three 
immune markers also had a trend of negative correlations with depressive symptoms, but this was 
not significant. The immune markers tended to be positively correlated with the core mania item 
“elevated mood”, which was significant with respect to sTNF-R1 (n=111, r=0.22, p=0.02). 
Severity of manic symptoms as measured with the total YMRS score was not significantly 
correlated to markers of inflammation.   
In SCH, neither YMRS, IDS nor core affective symptoms were significantly correlated with any 
immune parameters (Table 3, Study III).  
45 
 
Affective state groups:  The trend of higher immune markers with higher affect was significant 
after control for confounders for sTNF-R1 (p=0.02), OPG (p=0.04), IL-1Ra (p=0.02), while IL-6 
lost significance (p=0.09). After control for the combined effect of possible confounders the 
Depressed mood group of BP still had lower levels than Elevated mood group of TNF-R1 and of 
IL-1Ra (p=0.04 and p=0.02 respectively). The Depressed group also had significantly lower 
levels than Neutral mood group of OPG and IL-6 after control for confounding factors (p=0.004, 
and p=0.005 respectively). 
Comparisons with controls: After control for the combined effect of possible confounding 
factors the BP patients in the Neutral mood group still had significantly higher levels than 
controls of OPG (p=0.002) and IL-6 (, p=0.007) and patients in the Elevated mood group had 
higher levels of sTNF-R1 (p=0.009) and vWf (p=0.02). After control for the combined effect of 
possible confounding the SCH patients in Depressed mood group still had higher levels than 
controls of sTNF-R1 (p=0.005 but not of vWf (p=0.17), patients in Neutral mood group did not 
have higher vWf (p=0.17), and Elevated mood group did not have higher hsCRP (p=0.19) than 
controls. 
Affective symptoms: After control for confounders STNF-R1 was not significantly correlated 
with Elevated mood (p=0.20). After control for possible confounding factors the total IDS score 
was still significantly negatively correlated with OPG  (p=0.02), IL-6 (p=0.02) and IL-1Ra 
(p=0.01), and the core item  sad mood was still significantly negatively correlated with OPG 
(p=0.007),  IL-1Ra (p=0.009) and IL-6 (p= 0.005).  
9.4 Summary of results 
9.4.1 Patients had a specific immune profile 
The patients with severe mental disorder had a specific immune profile of highly significantly 
elevated TNF-R1, vWf and OPG, making it possible to suggest that these inflammatory pathways 
are more central to the pathology than other pathways.  
9.4.2 Bipolar disorder and Schizophrenia had similar immune profile  
Patients had highly significant elevations of inflammatory markers. Of the four general 
inflammatory markers, sTNF-R1 was highly significantly elevated (p<2x10-6), hsCRP was 
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elevated (p=0.008) but the association lost significance when divided into separate groups, IL-1β 
was elevated when compared strictly to time matched controls (p=0.007), but the association lost 
significance after control for possible confounding factors. IL-6 was not elevated. Of the three 
markers of more specific inflammatory markers, vWf was highly significantly elevated (p<2x10-
6), OPG was slightly elevated but the association was significant also after control for many 
possible confounders including CRP (p=0.01) while CD40L was not elevated. 
SCH and BPs had the same inflammatory profile, without any significant differences. 
9.4.3 Inflammation was inversely associated with degree of depression in bipolar disorder.  
Mania patients had the highest levels of inflammation, while depressed BP patients had low 
levels of all six inflammatory markers. Neutral mood had intermediate levels, and higher than 
controls. The severity of depressive symptoms was highly negatively correlated with OPG, IL-
1Ra and IL-6. Depressed BP patients had different immune profile from manic patients.  
 
 
10 Discussion  
10.1 High levels of inflammation in schizophrenia and bipolar disorder 
The investigations of this theses found that patients with severe mental disorders have elevated 
levels of general inflammatory marker (TNF-R1). The elevations of the general markers were 
highly statistically significant, were present in unmedicated as well as medicated patients and 
control for confounding factors did not change the results. In addition, the general marker hsCRP 
was slightly elevated. There was also some evidence of high IL-1Ra in patients, although it could 
not be excluded that this was due to confounding factors.  
The results are supported by other studies of immune related disturbances in severe mental 
disorders [108]. The study replicates findings of high inflammation reported in previous smaller 
studies.  According to the most recent review regarding inflammation in severe mental disorders 
from 2010, there are evidence of elevated  TNF-α, IL-1β and IL-6  in SCH, and of the same 
markers in BPs, although less evidence of elevated IL-6 [108]. The review did not include 
analysis of CRP and sTNF-RI, which has been found elevated in four recent studies [108, 211, 
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232-234]. The number of patients in the meta-analysis was approximately 450, which means that 
the 312 patients in the current study and the patients in the four other recent studies nearly 
doubles the number of cases, and strongly support that patients with severe mental disorders have 
elevated levels of general inflammatory markers [235]. 
The endothelial related inflammatory factor vWf was highly significantly elevated. Measures of 
this specific inflammatory marker have not been reported in severe mental disorder before. 
However, a previous study of psychotic disorders has reported association and genetic linkage 
between bipolar I disorder and the vWf gene [236]. Furthermore, in a study of depression in 
patients with cardiovascular disease, the vWf gene was the only gene out of 87 genes 
investigated, that was associated with depression [237].  In addition, in a study in healthy men, 
vWf was found to be associated with feelings of exhaustion and negative affect [238]. Four 
studies in severe mental disorders have investigated markers of endothelium function (ICAM and 
endothelin) in severe mental disorders, and two of them found elevated levels, and two found 
reduced [108].   These studies suggest that vWf is associated with mental symptoms, and support 
the current findings of increased vWf in severe mental illness.  
The calcium related marker OPG was also significantly elevated after control for confounding 
factors. The levels of the specific inflammation marker OPG has not been reported before in 
severe mental disorders, but two small studies have investigated OPG levels in depressive 
patients. OPG  was increased in patients with depressive disorder [239], and decreased in patients 
with depression and a former history of anorexia [240]. OPG  is related to calcium regulation, 
and the current result is in line with new research indicating that calcium signaling is of central 
importance in severe mental disorders [241].   
Contrary to the current findings, several studies have found elevated serum levels of IL-1β or IL-
1Ra in severe mental disorders although, there has been some inconsistencies [108]. IL-1β has, 
for instance been found both elevated and decreased in the cerebrospinal fluid of SCH patients 
[163, 242].  
Animal studies have suggested a role for IL-1Ra in behavior influenced by social isolation [243], 
and IL-1Ra increases after psychosocial stress [244]. Social withdrawal is one of the key features 
of negative psychotic symptoms, which has been associated with IL-1Ra in patients [245]. 
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Preliminary analysis of how IL-1Ra is related to psychotic symptoms, the current sample 
suggests that IL-1Ra is higher in patients with negative psychotic symptoms [246]. Thus, one 
could speculate if studies may find different levels of IL-1Ra depending on severity of negative 
symptoms.   
According to a meta-analysis, IL-6 is one of the general inflammatory markers which most 
studies have found elevated, especially in SCH [188]. The current results are, however,  in 
agreement with  recent findings of no increase of IL-6 in SCH [247], and lower IL-6 in the 
cerebrospinal fluid of BP patients than in healthy volunteers [248].  
CD40L has not been measured in previous studies of severe mental disorder. As the mean levels 
were non-significantly lower in patients than in controls, and as the marker did not have a large 
variation, it is unlikely that platelet related inflammatory pathways are of central importance to 
SCH or BP pathology. 
10.2 Specific immune profile of high TNF-R1, OPG and vWf 
The present results indicate a pattern of increased immune marker TNF, vWf and OPG. They  
were highly significantly elevated, also after controlling for confounding factors, while the four 
other markers were not.  
TNF-α  has been much investigated, There are several indications that patients have an immune 
profile characterized by high TNF-R1. According to a recent review, 10 immune markers have 
been investigated in two or more studies of severe mental disorders [108].Two of these immune 
markers were mainly of endothelial origin, four were mainly of monocytes/macrophage origin, 
and four were mainly of T-cell origin [108]. The analysis found evidence of elevated levels of the 
inflammatory markers from monocyte/macrophages, as TNF-α, IL-β, and IL-6, while 
inflammatory markers of other origins had been found consistently elevated.  The meta-analysis 
found that ten studies had reported elevated levels of TNF-α, seven had reported not significantly 
different levels, while no studies had reported reduced levels [108]. The meta-analysis, together 
with the current findings, strongly indicates that the inflammatory profile in patients with severe 
mental disorders is characterized by high activity in the TNF-pathways, as indicated by TNF-R1.  
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VWf was also highly significantly elevated after control for confounding factors. vWf is a not 
general inflammatory marker, but is a marker of endothelial activation and coagulation [249]. 
Four studies in severe mental disorders have investigated markers of endothelium function 
(ICAM and endothelin) in severe mental disorders, Two of them found elevated levels, and two 
found reduced [108].  In addition to vWf, OPG could also be described as related to endothelial 
dysfunction. OPG is constitutively secreted by endothelial cells [250, 251] and increases the 
adhesion of immune cells to the endothelium in the vessel walls [251]. Thus, the combined 
findings of elevated vWf and OPG indicate that patients have endothelial related inflammatory 
disturbances. New research supports that patients have endothelial dysfunction [252]. While 
earlier studies which investigated blood pressure and pulse wave variability did not find any clear  
disturbances [252], a new study found evidence of endothelial related dysfunction. Other aspects 
of vascular function, however, did not show any major disturbances [252]. This result is 
supported by a new study showing that the brain capillaries in SCH patients have structural 
abnormalities [253]. In addition, the susceptibility gene NOTCH4 elicits endothelial cell 
activation [254, 255]. That high levels of inflammation is related to endothelial inflammation is 
supported by that inflammatory genes were found to be altered in the brain endothelium of SCH 
patients [256]. Thus, it is reason to conclude that the patients’ immune profile is characterized by 
endothelial related inflammation.  
The inflammatory profile was also characterized by increased OPG, which indicates calcium 
related inflammatory disturbance. Osteoprotegerin is closely involved in calcium metabolism 
[176, 257].  Also vWf is influenced by calcium, as vWf  has a calcium binding site which 
regulates its cleavage [258]. Furthermore, calcium is important for the release of TNFR1 from 
endothelial cells [259]. The inflammatory profile of high OPG, vWf and sTNF-R1 could 
therefore be characterized as calcium related. The importance of calcium in the pathological 
mechanisms of severe mental disorders has been proposed in a calcium hypothesis, based on 
evidence that calcium may be an underlying disturbance causing disrupted dopamine and 
glutamate transmission [260]. That high inflammation is related to calcium disturbance is also 
supported by two studies reporting disturbed calcium in immune cells of patients [176, 257].  
To conclude, the results in the current thesis suggest a specific immune marker profile 
characterized by high levels of TNFR1, OPG and vWf, and more normal levels of hsCRP, IL-1β, 
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CD40L, and IL-6. This profile suggests TNF related, calcium related and endothelial related 
inflammatory disturbance.  
10.3 Similarities between schizophrenia and bipolar disorder 
The present study found that inflammatory pathways are activated in BP to the same extent as in 
SCH. This is in line with recent genetic studies, which have found that most susceptibility genes 
represent risk of both disorders [24]. Both disorders also have the same disturbance in stress 
hormone metabolism [261]. The disorders also share main morphological changes, as enlarged 
ventricles and reduced hippocampus [94].The same type of symptoms has also been found  
predictive of functioning irrespective of diagnosis [262]. 
The associations of immune markers and mood characteristics were only observed in BP. Even 
though the current BP sample showed less variation in mood, especially lower YMRS scores, 
compared to previous reports [201], there was still a significant correlation between severity of 
mood symptoms and inflammation. This may indicate that inflammation is involved in some 
specific pathological mechanisms in BP. However, it cannot be ignored that inflammatory 
markers have a role in affect regulation also in SCH, since there was less variation in mood 
symptoms compared to the degree of other symptoms.  
10.4 Large variation in immune markers 
The analysis in present thesis showed that the variation in inflammatory markers were larger in 
patients than in controls. A large variation in inflammatory levels among patients, have been 
presented also in other studies, although this has not been commented by the authors [193, 197, 
200, 263]. In the present study, OPG had higher variation among patients than controls. OPG has 
only been measured in two small previous psychiatric studies, including only 13 and 24 patients 
respectively. However, these two studies found opposite trends with respect to OPG levels in two 
samples of depressive patients differing with respect to having a history of anorexia [239, 240]. 
This suggests that different characteristics in subgroups of patients may explain some of the 
variation. Furthermore, a study found that there is a large variation in levels of polyunsaturated 
fatty acids (PUFA) among SCH patients [264]. Such PUFAs have been found to affect OPG 
levels [265, 266]. It has also been reported that there is a large unexplained variation in levels of 
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inflammatory markers in healthy persons [267]. A search for factors which may explain the large 
variation in inflammatory markers would therefore be interesting. 
10.5 Affective state and inflammatory markers 
10.5.1 High inflammation in bipolar disorder patients in manic state 
BP patients in manic state had the highest levels of four inflammatory markers. They had higher 
levels of sTNF-R1 than controls, and depressed patients. TNF-R1 was also positively correlated 
with degree of elevated mood. The findings are supported by a recent study reporting higher 
levels of TNF-R1 in BP mania,than in BP neutral affective state and in controls [232]. In 
addition, three studies which measured TNF-α found elevated levels in mania [193, 197, 200]. BP 
manic patients also had the highest levels of OPG, IL-1Ra and vWf compared to the other states 
of BP. Nine previous studies one or more inflammatory markers were associated with mania 
[188, 192-194, 196-200]. To conclude, the findings of high inflammation in mania, is supported 
by other studies, and seems best substantiated for the TNF-pathway.  
 
Although studies seem consistent in high inflammation in mania, this association is not in line 
with research on cytokine induced sickness behavior. It has been a well-accepted and much 
replicated finding in both animal and human research, that central inflammatory cytokines 
induces depressive mood, reduced energy and sleepiness. These are typical symptoms of 
infections, and many studies have shown that cytokines are mediators of these symptoms [189, 
191, 268]. In line with this, TNF-blocking medication has been found to reduce the risk of 
depression in patients with autoimmune disease [269]. Other symptoms of mania, such as 
decreased need for sleep, increased energy and talkativeness are also quite opposite from 
symptoms in sickness behavior. It remains a puzzle why BP patients with high levels of 
inflammation have elevated mood. 
10.5.2 Normal levels of inflammation in bipolar depression 
Bipolar depressed patients had lower levels of inflammation than those in neutral state and manic 
state, and approximately equal levels as controls. They had non-significantly lower levels of IL-
1β, IL-6 and hsCRP than controls. This was an unexpected finding, as unipolar depression has 
been associated with high levels of inflammation. 
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There are few published studies of bipolar depression, most with small samples. One study, 
however, reported high levels of TNF in 9 patients, another found high IL-1β in 10 patients, a 
third found high hsCRP in 30 patients [197, 198, 200]. Another reported that CRP was correlated 
with severity of depression in 30 bipolar depressed patients [198]. However, a recent study found 
equal levels of TNF-α in 24 depressive patients [201], another found equal levels of hsCRP in 20 
bipolar depressed patients [199]. Importantly, the largest study so far, found no correlation 
between depression and inflammatory markers in 122 BP patients [192].  
The current findings of low inflammation in depression and high in mania seems in also in line 
with a study reporting an inverse pattern of cytokine levels in mania and depression [200]. Thus, 
it seems as the findings in the present thesis is supported by some recent studies.  
Many studies has found elevated levels of inflammation in major depression, but according to a 
new meta-analysis, there is only evidence of high TNF and IL-6 , while IL-1β is non-significantly 
lower [190]. Several studies have also reported low inflammation in depression. Studies have 
reported low IL-6, CRP [270-272], OPG [240], TNF and TNF-R1 [164, 270-275] in depression.  
A negative correlation between vWf and depressed mood has also been observed [238]. 
Furthermore, several studies has reported that that treatment effect of antidepressive medications 
is associated with increasing levels of TNF-R1  [276, 277],  IL-6 [278, 279] and IL-1 [276, 277, 
280], which supports that patients may have low inflammation in depressive state, that normalize 
into a higher level after treatment response. A recent review has described that depression seems 
characterized by both immune activation and suppression [281]. Further, unipolar and bipolar 
depression has differences in symptom profiles and pathophysiology [282]. This makes it is 
possible that bipolar depression is characterized by lower levels of inflammation than unipolar 
depression. More studies are needed to elucidate this possibility.   
There were highly significant correlations between severity of depressed mood and low 
inflammatory markers in BP patients. The trend was similar for all markers, but was only 
significant for OPG, IL-1Ra and IL-6. The associations were significant for both the core 
depressive symptom sad mood, and for the total score on IDS. None of the previous studies in BP 
patients has reported such an association between severity of mood symptoms and serum 
markers. However, in one study, a negative correlation between degree of depression and sTNF-
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R1 was found. The correlation coefficient was approximately as high as in this study, but as the 
study had included fewer patients, the association was statistically non- significant [232]. 
Nevertheless, the study that found a similar trend as in this theses supports that the findings of 
low inflammation in bipolar depression may be a valid result.  
HsCRP and IL-6 were differently associated with affective state than the other markers. Patients 
in neutral state had higher levels of IL-6 than depressed and manic. According to a recent review, 
there is less evidence of elevated IL-6, than of TNF-α and IL-1β in severe mental disorders [188]. 
According to a new study, patients with low levels of IL-6 had good treatment response to anti-
depressive medication, and treatment response was associated with increasing IL-6 levels [283]. 
Another study reported that high levels of IL-6 in depression were associated with poor treatment 
response [284]. These two studies seem to support that low levels of IL-6 may be a valid finding 
in depression. Furthermore, IL-6 has been found to be more associated with anxiety and 
irritability than with feelings of depression [285]. This suggests that high levels of IL-6 in some 
previous studies may have been caused by comorbid symptoms as anxiety and irritability, while 
the low levels in this study, could have been due to less anxious and irritable patients. . 
10.6 Methodological issues 
The current thesis has some limitations. The studies are cross-sectional, as most studies in the 
field of immunology in psychiatry, and this limits the discussion of causality.  
Although the results were controlled for many confounders, it cannot be ruled out that 
confounding factors are present. Differences in smoking habits could be such a confounder, but 
smoking were not significantly correlated to the inflammation markers. Furthermore, it has been 
shown that smoking cessation does not change the levels TNF-RI or vWf [286]. OPG has been 
reported to be low in smokers, supporting that the high OPG in patients is not caused by 
smoking.  
Antipsychotic medication has been associated with both inflammatory and anti-inflammatory 
effects [287, 288]. However, in the present study, there was no difference in inflammation 
between medicated and unmedicated patients. This is in line with a recent review, where it was 
concluded that markers as TNF-α was not significantly affected by antipsychotic treatment [235]. 
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Furthermore, despite different drug regimens, the two diagnostic groups showed similar profiles 
of inflammatory parameters.  
It cannot be ignored that the present results may be affected by differences in non-fasting status 
[167]. However, this is not likely since the results were controlled for many factors that usually 
are associated with fasting status.  Furthermore, as shown in table 1, study III, patients in this 
study did not have elevated levels of glucose, and triglycerides. It is not likely that any 
differences in fasting status have had any large impact on levels of inflammatory markers, when 
not having impact on glucose and triglycerides.  
It is a possibility that some patients may have a shift in affective status between time of clinical 
assessment and blood sampling. However, the duration of mood episodes is usually long, with a 
median length of 3 months and even after remission, the symptom profile tend to have 
similarities with the polarity of last affective episode [58, 289]. This makes it unlikely that 
affective shift had any major influence on the results.  
 
It is also unlikely that differences in autoimmune disease could explain the study result, because 
having a diagnosis of autoimmune disease was not significantly associated with higher levels of 
inflammation. Furthermore, the low inflammation in the BP depression could not be due to 
autoimmune diseases, as the frequency of autoimmune diseases was equally distributed in the 
affective groups.  
 
Patients did not have significantly higher IL-1Ra, which is in contrast to a recent review reporting 
high IL-1β in patients.  However, this study measured IL-1Ra instead of IL-1β. A rather low 
correlation between IL-1β and IL-1Ra measurements has been reported in one study[209]. 
Moreover, IL-1β circulates at low levels just above the detection limit of various assays, and thus 
IL-1Ra is regarded as a more stable and reliable marker of the activity in the IL-1 system, better 
than IL-1β itself.  TNF-R1 is also regarded a more stable and reliable marker than TNF-α [203, 
210], which could explain why this study had very significant elevations.  
 
In addition, differences regarding sample size, disease severity and comparison groups makes it 
difficult to compare the studies [167]. This current study is the largest so far. In addition, we 
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controlled the results for more possible confounders than previous studies. This reduces the risk 
that the associations are a result of chance findings.   
10.7 Underlying mechanisms 
10.7.1 Possible factors leading to high TNF 
10.7.1.1 Genetic factors 
It is still uncertain which genetic factors that influence serum levels of TNF-R1 in clinical 
samples [290]. In a large whole genome study, the five top genetic susceptibility loci were in the 
extended MHC region. The gene for TNF-α is the only cytokine, which also lies in the extended 
MHC region. This region has strong linkage making it difficult to evaluate the impact of any 
single gene, as many genes are often inherited together [107].  NOTCH4 is a MHC gene 
associated with risk of severe mental disorders. This gene is regulated by TNF-α [254]. In 
addition, the susceptibility gene PLAA [291] influences TNF-α expression [292]. The  
complement controlled gene CSMD1,has also been associated with SCH [293], and this gene is 
associated with susceptibility to several viral infections [294]. Thus, it is possible that genetic 
factors could be a cause of high TNF-R1.  
10.7.1.2 Autoimmune reactions 
The analysis in this theses found no evidence that high TNF-R1 in patients is due to autoimmune 
diseases. Still, it is possible that autoimmune processes could be a cause of high inflammation.  
Autoimmune reactions can occur in all organs, including the brain, and autoantibodies to 
different types of brain molecules has been reported in SCH [295]. High levels of autoimmune 
antibodies has also been found in their serum [15, 296]. As high TNF is is a typical characteristic 
of autoimmune diseases, it may be undiagnosed autoimmune processes which contribute to high 
inflammation in patients. 
10.7.1.3 Mental stress 
High levels of interpersonal stress have been found predictive of high inflammation [297]. 
Patients with severe mental disorders are vulnerable to mental stress, and to critical comments 
and negative communication with  family members [298]. This type of communication has been 
found to induce increased levels of TNF-α [299].  Furthermore, psychological stressors and 
immune challenges may have synergistic effect on the induction of inflammatory markers [151]. 
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10.7.1.4 Neurotropic infections 
Viruses in the herpes family are the ones which most consistently has been associated with 
increased risk of SCH. Herpes viruses are neurotropic and reside within cells in a latent phase. 
This means that when first infected, the person is infected for the rest of his life. Approximately 
70% of adults have been infected with HSV1 [102]. HSV1 infects the face, gets access directly to 
the brain stem through the fifth brain nerve, and commonly resides within the trigeminal ganglion 
in the brain stem, which is a region affected in severe mental disorders [94]. A study 
investigating TNF-α expression in neurons infected by HSV1, found TNF-α expression in nearly 
100% of of the trigeminal neurons. In contrast, TNF-α was not detected in neurons free of HSV1 
[300].  It could be speculated that if there are more neurons infected in patients, it could probably 
induce higher levels of TNF-α.  
From the brain stem, HSV1 may reactivate from its latency and infect the brain causing 
encephalitis. In such cases it preferentially affects the temporal cortex and limbic structures 
[301]. An acute infection increases dopamine transmission [302] and typical symptoms are 
headache, personality changes, hallucinations, cognitive disturbances, impaired consciousness 
and convulsions [303]. Although an acute infection resolves rapidly, it may induce progressive 
brain morphological changes including increased brain ventricle sizes [304, 305].  It mainly 
infects limbic structures as the hippocampus [305].  An acute HSV encephalitis infection may 
show no signs of infection in the cerebrospinal fluid [305] and a rise in antibody titers cannot be 
used to detect reactivations of the viruses [103]. The ability to  induce pathological disturbances 
seen in severe mental disorders, make them  therefore difficult to detect.   
In line with this, a small post-mortem study found HSV in 4 out of 6 hippocampus samples from 
SCH patients. None of them have had any known encephalitis [306].   
As mentioned, antibodies to HSV1 has also been associated with poorer cognition and smaller 
brain volumes in BP and SCH and an association between HSV1 and cognition has also been 
found in healthy persons [46-48, 50, 51, 97, 307, 308].  
Another cause of high TNF- α may be cytomegalovirus. This virus is associated with risk of SCH 
[309, 310] as well as with increased levels of TNF-α. [311]. Cytomegalovirus preferentially 
infects glial cells and macrophages in the brain, but neurons may also be infected. In line with 
this, cytomegalovirus has also been found to induce neuronal death [311]. Cytomegalovirus may 
be difficult to detect, as infected neurons may not show any antigens [311, 312].  
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10.7.2 Possible factors leading to high vWf and OPG 
10.7.2.1 Genetic factors/neurotransmitters. 
One factor that possible can participate in the increased vWf and OPG levels may be genetic. The 
CACNA1c is a much replicated susceptibility gene [241]. The gene encodes a calcium channel 
with immune modulating effects [313], and regulates the expression and secretion of OPG [314]. 
Thus, it could be speculated that high OPG levels may be caused by genetic variants in the 
CACNA1c gene.  The CACNA1c channel contains a domain consisting of vWf. This domain is a 
key regulator of influx though the channel [315]. In addition, the cleavage of vWf has recently 
been  found to be influenced by calcium [258].  VWf has a calcium-binding site that regulates its 
cleavage. It makes it possible that high vWf may be due to genetic susceptibility [258]. In 
addition, the complement related susceptibility genes CSMD 1 and 2 could be a cause of high 
vWf [293], as the complement cascade increases release of vWf [105]. Another newly discovered 
susceptibility gene called NOTCH4 may also be a cause of high vWf, as it is associated with 
endothelial dysfunction [254, 255].  
High levels of vWf may also be caused by changes in monaminergic neurotransmission as the 
release of vWf is increased as response to epinephrine, and is inhibited by dopamine [316]. 
10.7.2.2 Neurotropic patogens 
VWf is expressed at higher levels in endothelial cells infected with the cytomegalovirus infection 
[317, 318], which makes it likely that cytomegalovirus, as a risk factor of severe mental 
disorders,  may be one possible cause of  high levels of vWf [37]. Cytomegalovirus antibodies 
has been found predicative of high vWf levels as long as 15 years after the first measurement 
[319]. This supports that even fetal infection which is associated with increased risk of SCH, may 
induce high levels of vWf [320, 321]. That this may be an underlying cause of vWf is therefore 
potentially important.  
HSV could be speculated to be a cause of high calcium related inflammation, as it harness 
calcium signaling to facilitate viral entry [322]. 
10.7.3 Possible factors underlying high inflammation in mania 
High inflammation induces sickness behavior, which is characterized by opposite behavior from 
those seen in mania. It is a puzzle why BP patients with high inflammation have elevated mood, 
when the typical is to have reduced mood. One possible mechanism may be that it due to 
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interactions with pathogens. Herpes, cytomegalovirus and toxoplasma tend to increase dopamine 
levels [302, 323].  Dopamine neurons is mediators in the reward system, and increases the 
feelings of pleasure [324]. It is possible that the pathogens increase dopamine levels, and thereby 
causes a feeling of elevated mood, as well as inducing high levels of inflammation [325]. 
  
10.7.4 Possible causes factors underlying low inflammation in depression 
It was a somewhat unexpected finding that depressive state of BP had the lowest levels of 
inflammation. It could be speculated if this is related to levels of catecholamine neurotransmitters 
which has been reported to be low in depression and high in mania [326]. High levels of 
catecholamines (norepinephrine and dopamine) have been found to increase inflammation, and 
vice versa [327, 328]. However, these neurotransmitters have also been reported to have immune 
suppressive effects [329]. Not only do neurotransmitters influence cytokines, it is also the 
opposite way around [330-332]. Thus, it is still unclear how the immune system interacts with 
neurotransmitters. The interaction may be influenced by many unknown factors making it 
difficult understand the mechanisms. 
 
Although acute stress may cause elevated inflammation, long-term psychosocial stress has been 
found to lower inflammation [333, 334]. The mechanisms involved are complicated and how the 
stress influences immune responses may vary, and depending on many factors as i.e. timing. 
Thus, it is possible that low levels of inflammation in depressed BP patients may be related to 
long-term psycho-social stress.   
Although pathogens associated with severe mental disorders may cause high inflammation, they 
also have some immune suppressing effects [335-337]. They may also have specific immune 
modulating effects, elevating some cytokines, while inducing a restricted reduction of others 
[338]. Furthermore, when the immune defence fights the neurotropic infections in 
cathecholamine producing neurons, it may result in a reduced number of catecholamine 
producing neurons. This mechanism has been suggested as a cause of high risk of depression 
following HSV encephalitis [339].  
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10.7.5 Possible consequences of high TNF-R1, vWf and OPG  
10.7.5.1 Cognitive impairment 
Cognitive impairment is an important predictor of poor treatment outcome in patients with severe 
mental disorders, and experts have suggested that improving cognitive function should be a 
treatment target [10, 71, 72]. Therefore, it is of importance that high levels of TNF-R1 induce 
cognitive impairments in animals, and are predictive of cognitive impairment in humans.   
Many animal studies have found that high levels of systemic inflammation induces 
neurodegenerative effects in the brain [340], and that high TNF induces detrimental effects on 
cognition [154]. The impact on longstanding elevations in TNF may be substantial, as a high 
level of TNF-α  for 100 days has been found to induce neurodegeneration and loss of 75% of the 
dopamine neurons in the striatum of mice [341]. The apoptosis inducing domain of TNF-R1 has 
been found to mediate neurodegenerative processes in an animal model of dementia [116], and 
medication which specifically reduce the TNF-R1 signaling has been suggested as treatment for 
neurodegenerative diseases [155].   
In line with the animal studies, high levels of TNF / TNF-R1 has been found predictive of 
cognitive impairment in humans.  In a study of 1037 healthy older persons, those with high TNF-
α had poorer cognitive abilities [342]. In a study of 691 healthy individuals those who had higher 
TNF-α had an increased risk of cognitive decline during the next years [158]. In line with this, a 
study of 1430 healthy persons found that high levels of TNF-α was associated with smaller brain 
volumes [343]. TNF-R1 has also been found to correlated with a marker of axonal damage called 
tau in both healthy persons and patients with mild cognitive impairment [205]. The levels of 
TNF-α and TNF-R1 has also been found predictive of further cognitive decline in patients with 
mild cognitive impairment [205, 344]. In those who already have dementia, acute systemic 
inflammatory events with high TNF-α dramatically increased the rate of cognitive decline over a 
6-months period. In contrast, patients who had low levels of serum TNF-α throughout the study 
showed no further cognitive decline [345].  To summarize, high TNF-α /TNF-R1 has been found 
to induce memory impairment in animals, and to be predictive of memory impairments in healthy 
persons, in persons with mild cognitive decline and in those with dementia. Thus, it seems 
reasonable to assume that also in patients with severe mental disorder, high levels of TNF-R1 
will imply risk of memory impairment.  
60 
 
10.7.5.2 Risk of cardiovascular disease 
Each of the inflammatory factors vWf, TNF-R1, OPG, hsCRP and IL-1Ra is associated with 
increased  risk of cardiovascular disease and coagulation disturbances [171, 346-348]. 
HsCRP has been much investigated as a risk factor of cardiovascular disease [102].  The risk 
associated with high hsCRP, has been found independent of the risk associated with high sTNF-
R1, vWf and OPG [171, 184, 347].  VWf was reported to be more predictive of both 
cardiovascular disease and of mortality from all causes, than hsCRP [171].  In addition, TNF-R1 
has been reported to be more predictive of CVD mortality than hsCRP. In two prospective 
studies, including 660 and 1400 patients, sTNFR1, but not hsCRP, was independently associated 
with pathological heart changes and mortality [347, 349]. Furthermore, a quite new study 
including 1400 persons found that TNF-R1 was predictive of CVD mortality independent of 
other factors [290]. 
OPG has been investigated in more than 300 studies related to cardiovascular disease. It has been 
associated with prevalence and severity of coronary artery disease, cerebrovascular disease and 
peripheral vascular disease, and to be predictive of mortality in different populations and disease 
categories. Circulating OPG levels are increased in patients with acute coronary syndrome. 
Enhanced expression has been found within symptomatic carotid plaques and OPG has been 
reported to predict survival in patients with heart failure after acute myocardial infarction, to 
predict heart failure hospitalization and mortality in patients with acute coronary syndrome. It is 
also associated with long-term mortality in patients with ischemic stroke [184].  It is previously 
reported that OPG levels, comparable to those found in the patients group in the present study, 
(above 2.3 – 2.9 ng/ml) are associated with increased cardiovascular morbidity or mortality in 
patients with stroke or acute coronary syndrome [350, 351]. Also in the general population, 
elevated OPG levels have been associated with the degree of coronary calcification as a marker 
of coronary atherosclerosis. Importantly, OPG has been found predictive of cardiovascular 
disease, independent of traditional  risk factors in a large population based study, investigating 
healthy individuals, and also after control for traditional risk factors for cardiovascular disease 
[352].  
The good properties of OPG as a marker of CVD has been suggested to be due to its properties as 
a stable marker of activity in the RANKL/OPG/RANK axis, as well as it is thought to mirror the 
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activity in  pathways with relevance to atherosclerosis, as inflammation and vascular calcification 
[184].   
This means that the inflammatory profile found in this theses, strongly suggests that patients have 
elevated risk of cardiovascular disease. 
  
11 Generalizability of results and implications for further 
research.  
11.1 Generalizability of the current results 
The patients in the study are included from a catchment area, and are assumed representative for 
the average patients receiving treatment at this level. The study has the also the advantage of 
having a large sample size. According to this, it could be assumed that results are generalizable to 
other clinical samples of patients with the same diagnosis.  
The selection of patients in the study is probably slightly better functioning patients, 
understanding the importance of contributing to research. However, this is a general problem in 
clinical studies that depend on informed consent.  
11.2 Implications for further research 
Immunosuppressive medications as Non Steroid Anti Inflammatory Drugs (NSAID), Aspirin and 
TNF-inhibitors have been suggested as treatment for patients with severe mental disorders [353, 
354]. Some placebo-controlled trials have also found anti-inflammatory drugs effective as 
adjunctive therapy against SCH and BPs [355, 356]. However, there was a large variance in 
inflammatory levels among patients. Especially bipolar depressed patients did not have elevated 
levels. They will probably not benefit from further reductions of the inflammatory mediators. 
Furthermore, there is a possibility that anti-inflammatory medications will have a negative effect 
in patients who have neurotropic infections. Moreover, lithium has been found to increase TNF in 
healthy persons and to have immune stimulatory effects [99, 357].   
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Further research is needed to find out what causes the increased inflammation, and if there are 
patients with specific symptoms of inflammatory profile who will benefit from adjunctive 
treatment with anti-inflammatory medications.     
Patients with severe mental disorders have reduced brain volumes, and cognitive impairments, 
[32, 358]. As TNF has been associated with both cognitive impairments and reduced brain 
volume, further research is needed to find out if patients with high levels of TNF-R1 are more 
cognitively disturbed and at risk of cognitive decline.  Longitudinal studies investigating if levels 
of inflammatory markers normalize in remission and if levels fluctuate depending on relapse of 
affective symptoms are needed. Further studies on whether symptom profile and comorbid 
diseases may explain variation in inflammation are also needed. 
 
12 Conclusions 
The theses aimed to increase the understanding of the role of systemic inflammation in severe 
mental disorders. The major conclusions are as follows:  
 The investigations determined levels of inflammation in patients with severe mental 
disorder and found that they have highly significant elevations, also after controlling for 
many confounding factors.  
 The results indicate that specific inflammatory pathways were disturbed. There were 
specific elevations in the general inflammatory marker TNF-R1, in the endothelial related 
von Willebrand factor and in the calcium related marker OPG.  
 The inflammatory profile does not differ between patients with BP and SCH.  
 The study found that inflammatory markers were associated with affective state.  BP 
patients with elevated mood had the highest levels of inflammatory markers and bipolar 
depressed patients had the lowest.  
 Severity of depression was inversely correlated with inflammation, which was significant 
for IL-1Ra, IL-6 and OPG.  
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The results show that inflammatory disturbances are of importance in severe mental disorders and 
suggests that they may be involved in abnormal affective regulation in BP.  
.   
13 Errata 
In table 1, study II, it says that No of controls smoking were Zero (0), but the correct should be 
missing (-).  
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14 Full text articles of study I, II an II 
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